US20210213301A1 - Dual-stage syringes for independent delivery of two or more fluids - Google Patents
Dual-stage syringes for independent delivery of two or more fluids Download PDFInfo
- Publication number
- US20210213301A1 US20210213301A1 US17/056,034 US201917056034A US2021213301A1 US 20210213301 A1 US20210213301 A1 US 20210213301A1 US 201917056034 A US201917056034 A US 201917056034A US 2021213301 A1 US2021213301 A1 US 2021213301A1
- Authority
- US
- United States
- Prior art keywords
- syringe
- stage
- plunger
- dual
- primary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012530 fluid Substances 0.000 title claims description 49
- 230000007246 mechanism Effects 0.000 claims description 81
- 238000000034 method Methods 0.000 claims description 37
- 230000010110 radioembolization Effects 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 18
- 239000011324 bead Substances 0.000 claims description 15
- 230000013011 mating Effects 0.000 claims description 12
- 238000006073 displacement reaction Methods 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 230000005291 magnetic effect Effects 0.000 description 61
- 239000000463 material Substances 0.000 description 42
- -1 polyethylenes Polymers 0.000 description 33
- 239000004005 microsphere Substances 0.000 description 32
- 230000005855 radiation Effects 0.000 description 26
- 229910052751 metal Inorganic materials 0.000 description 23
- 239000002184 metal Substances 0.000 description 23
- 150000002739 metals Chemical class 0.000 description 23
- 229920000642 polymer Polymers 0.000 description 16
- 239000004417 polycarbonate Substances 0.000 description 15
- 229920000515 polycarbonate Polymers 0.000 description 15
- 229920003023 plastic Polymers 0.000 description 14
- 239000004033 plastic Substances 0.000 description 14
- 239000004698 Polyethylene Substances 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 229920000573 polyethylene Polymers 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 12
- 229920000139 polyethylene terephthalate Polymers 0.000 description 11
- 230000002285 radioactive effect Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 238000004891 communication Methods 0.000 description 9
- 229910045601 alloy Inorganic materials 0.000 description 8
- 239000000956 alloy Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000007373 indentation Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 8
- 239000004926 polymethyl methacrylate Substances 0.000 description 8
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 8
- 229910052721 tungsten Inorganic materials 0.000 description 8
- 239000010937 tungsten Substances 0.000 description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 229910052802 copper Inorganic materials 0.000 description 7
- 239000010949 copper Substances 0.000 description 7
- 229910001092 metal group alloy Inorganic materials 0.000 description 7
- 239000010935 stainless steel Substances 0.000 description 7
- 229910001220 stainless steel Inorganic materials 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000003439 radiotherapeutic effect Effects 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 239000000805 composite resin Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 239000002889 diamagnetic material Substances 0.000 description 4
- 239000011133 lead Substances 0.000 description 4
- 229910000498 pewter Inorganic materials 0.000 description 4
- 239000010957 pewter Substances 0.000 description 4
- 229920002725 thermoplastic elastomer Polymers 0.000 description 4
- 229920006342 thermoplastic vulcanizate Polymers 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000560 biocompatible material Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000012857 radioactive material Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 206010073306 Exposure to radiation Diseases 0.000 description 2
- 206010073069 Hepatic cancer Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000012611 container material Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 230000005294 ferromagnetic effect Effects 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229940071643 prefilled syringe Drugs 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 150000002910 rare earth metals Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002943 EPDM rubber Polymers 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004734 Polyphenylene sulfide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 229910000828 alnico Inorganic materials 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical class C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 229920001973 fluoroelastomer Polymers 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 238000002697 interventional radiology Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229910001172 neodymium magnet Inorganic materials 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000069 polyphenylene sulfide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 229910000938 samarium–cobalt magnet Inorganic materials 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/10—Tube connectors; Tube couplings
- A61M39/1011—Locking means for securing connection; Additional tamper safeties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/0105—Steering means as part of the catheter or advancing means; Markers for positioning
- A61M25/0133—Tip steering devices
- A61M25/0147—Tip steering devices with movable mechanical means, e.g. pull wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1255—Granulates, agglomerates, microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0009—Making of catheters or other medical or surgical tubes
- A61M25/0012—Making of catheters or other medical or surgical tubes with embedded structures, e.g. coils, braids, meshes, strands or radiopaque coils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
- A61M25/003—Multi-lumen catheters with stationary elements characterized by features relating to least one lumen located at the distal part of the catheter, e.g. filters, plugs or valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
- A61M25/0071—Multiple separate lumens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/008—Strength or flexibility characteristics of the catheter tip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0082—Catheter tip comprising a tool
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/0105—Steering means as part of the catheter or advancing means; Markers for positioning
- A61M25/0108—Steering means as part of the catheter or advancing means; Markers for positioning using radio-opaque or ultrasound markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/09—Guide wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/10—Tube connectors; Tube couplings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/1407—Infusion of two or more substances
- A61M5/1409—Infusion of two or more substances in series, e.g. first substance passing through container holding second substance, e.g. reconstitution systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14212—Pumping with an aspiration and an expulsion action
- A61M5/14216—Reciprocating piston type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
- A61M5/1456—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons with a replaceable reservoir comprising a piston rod to be moved into the reservoir, e.g. the piston rod is part of the removable reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
- A61M5/14566—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons with a replaceable reservoir for receiving a piston rod of the pump
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/16804—Flow controllers
- A61M5/16809—Flow controllers by repeated filling and emptying of an intermediate volume
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/1785—Syringes comprising radioactive shield means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M5/2448—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic comprising means for injection of two or more media, e.g. by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/31571—Means preventing accidental administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1002—Intraluminal radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1007—Arrangements or means for the introduction of sources into the body
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00529—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
- A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M2005/1787—Syringes for sequential delivery of fluids, e.g. first medicament and then flushing liquid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2403—Ampoule inserted into the ampoule holder
- A61M2005/2414—Ampoule inserted into the ampoule holder from the side
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M5/2455—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic with sealing means to be broken or opened
- A61M5/2466—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic with sealing means to be broken or opened by piercing without internal pressure increase
- A61M2005/247—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic with sealing means to be broken or opened by piercing without internal pressure increase with fixed or steady piercing means, e.g. piercing under movement of ampoule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31596—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms comprising means for injection of two or more media, e.g. by mixing
- A61M2005/31598—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms comprising means for injection of two or more media, e.g. by mixing having multiple telescopically sliding coaxial pistons encompassing volumes for components to be mixed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M2025/0004—Catheters; Hollow probes having two or more concentrically arranged tubes for forming a concentric catheter system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
- A61M25/003—Multi-lumen catheters with stationary elements characterized by features relating to least one lumen located at the distal part of the catheter, e.g. filters, plugs or valves
- A61M2025/0031—Multi-lumen catheters with stationary elements characterized by features relating to least one lumen located at the distal part of the catheter, e.g. filters, plugs or valves characterized by lumina for withdrawing or delivering, i.e. used for extracorporeal circuit treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
- A61M2025/0036—Multi-lumen catheters with stationary elements with more than four lumina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
- A61M2025/004—Multi-lumen catheters with stationary elements characterized by lumina being arranged circumferentially
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M2025/0042—Microcatheters, cannula or the like having outside diameters around 1 mm or less
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
- A61M2025/0073—Tip designed for influencing the flow or the flow velocity of the fluid, e.g. inserts for twisted or vortex flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0074—Dynamic characteristics of the catheter tip, e.g. openable, closable, expandable or deformable
- A61M25/0075—Valve means
- A61M2025/0076—Unidirectional valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/008—Strength or flexibility characteristics of the catheter tip
- A61M2025/0081—Soft tip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/06—Body-piercing guide needles or the like
- A61M25/0662—Guide tubes
- A61M2025/0681—Systems with catheter and outer tubing, e.g. sheath, sleeve or guide tube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/09—Guide wires
- A61M2025/09058—Basic structures of guide wires
- A61M2025/09075—Basic structures of guide wires having a core without a coil possibly combined with a sheath
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/09—Guide wires
- A61M2025/09166—Guide wires having radio-opaque features
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/10—Tube connectors; Tube couplings
- A61M2039/1027—Quick-acting type connectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/10—Tube connectors; Tube couplings
- A61M2039/1033—Swivel nut connectors, e.g. threaded connectors, bayonet-connectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/10—Tube connectors; Tube couplings
- A61M2039/1072—Tube connectors; Tube couplings with a septum present in the connector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/14—Detection of the presence or absence of a tube, a connector or a container in an apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/32—General characteristics of the apparatus with radio-opaque indicia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3306—Optical measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3317—Electromagnetic, inductive or dielectric measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3327—Measuring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3334—Measuring or controlling the flow rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
- A61M2205/505—Touch-screens; Virtual keyboard or keypads; Virtual buttons; Soft keys; Mouse touches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8206—Internal energy supply devices battery-operated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/11—Laminar flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/204—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically connected to external reservoirs for multiple refilling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N2005/1019—Sources therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1048—Monitoring, verifying, controlling systems and methods
- A61N2005/1074—Details of the control system, e.g. user interfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1089—Electrons
Definitions
- the present disclosure relates generally to syringes and, more particularly, to dual-stage syringes that deliver multiple fluids independently.
- radioactive therapeutic agents can be harmful and potentially lethal to patients or medical personnel. Accordingly, medical instruments for radiation therapies must be configured to localize the delivery of radioactive material to a particular area of the patient's body while shielding others from unnecessarily being exposed to radiation.
- Transarterial Radioembolization is a transcatheter intra-arterial procedure performed by interventional radiology and is commonly employed for the treatment of malignant tumors.
- a microcatheter is navigated into a patient's liver, where radioembolizing microspheres loaded with a radioactive compound, such as yttrium-90 ( 90 Y or Y90), are delivered to the targeted tumors.
- the microspheres embolize blood vessels that supply the tumors while also delivering radiation to kill tumor cells.
- medical devices for performing radioembolization procedures require multiple syringes, external tubing, a vial containing the radioactive compound, and a bulky shield assembly for containing and shielding the radioactive vial.
- Such devices typically involve time consuming and labor-intensive setup procedures.
- the complex devices are commonly stationary and thereby limit a physician's mobility in an operating room to within a certain proximity of the device.
- Routine manipulation of a product container storing radioactive material during radioembolization procedures generally requires a Nuclear Medicine Technician, who handles the material with forceps or tweezers. This process involves further potential of exposing additional medical personnel to radioactivity, and contaminating the operating room. Syringes for manually administering the radioactive compound are prone to inconsistent flow rates and pressures. Insufficient injection rates result in decreased bead dispersion, which may impact efficacy of the treatment.
- Embodiments of the present disclosure are to be used in any technical setting where it is necessary to deliver two separate and isolated media, such as during Transarterial Radioembolization for the treatment of malignant liver tumors.
- a Transarterial Radioembolization procedure a microcatheter is navigated into the liver, and a therapeutic agent, such as a radiotherapeutic agent included in microspheres, may be delivered to the targeted tumors.
- a therapeutic agent such as a radiotherapeutic agent included in microspheres
- different media including saline/D5W, contrast agent, and the microspheres.
- the first syringe may be an empty or prefilled syringe of saline for pumping. During the exchange of two or more independent syringes, there is a risk of air entering the system.
- This disclosure describes a dual-stage syringe having two independent reservoirs that are engaged in series via a single plunger for the injection or distribution of two separate media.
- the dual-stage syringes disclosed herein may be manually driven.
- the dual-stage syringes of the present disclosure may include a single plunger mechanism, which is used to actuate both chambers, and the medium in each chamber is delivered independently.
- the dual-stage syringes of the present disclosure may allow for the internal or proximal chamber to be filled and purged multiple times without actuating the external or distal chamber.
- some embodiments of the dual-stage syringes disclosed herein may include one or more locking mechanisms, which may provide tactile and audible feedback and assurance for when the various media are exchanged.
- Embodiments of the present disclosure may also address one or more of the following shortcomings of existing systems: Difficulty in pushing syringes to pressurize liquids to flow through the microcatheter, numerous cumbersome steps that delay the procedure and cause unnecessary radiation exposure (e.g.
- Example embodiments disclosed herein are directed to locking-mechanism dual-stage syringes.
- FIG. 1 is a schematic of a dual-stage syringe according to embodiments.
- FIG. 2 is a side view of an external barrel of a dual-stage syringe according to embodiments.
- FIG. 3 is a top perspective view of an external barrel of a dual-stage syringe according to embodiments.
- FIG. 4 is a bottom perspective view of an external barrel of a dual-stage syringe according to embodiments.
- FIG. 5 is a side perspective view of an external barrel of the dual-stage syringe according to embodiments.
- FIG. 6 is a side view of a primary plunger of a dual-stage syringe according to embodiments.
- FIG. 7 is a top perspective view of a primary plunger of a dual-stage syringe according to embodiments.
- FIG. 8 is a side perspective view of a primary plunger of a dual-stage syringe according to embodiments.
- FIG. 9 is a side perspective view of a primary plunger of a dual-stage syringe, including a sealing member on the distal end thereof, according to embodiments.
- FIG. 10 is a side perspective view of a primary plunger of a dual-stage syringe, including a sealing member on the distal end thereof, according to embodiments.
- FIG. 11 is an exploded view of a sleeved dual-stage syringe according to embodiments.
- FIG. 12 is a side perspective view of a locking sleeve, according to embodiments.
- FIG. 13 is a bottom perspective view of the locking sleeve, according to embodiments.
- FIG. 14 is a bottom view of the locking mechanism of the locking sleeve, according to embodiments.
- FIG. 15 is a top perspective view of the locking sleeve, according to embodiments.
- FIG. 16 is a side perspective view of an assembly including the locking mechanism and the primary plunger having a sealing member on the distal end thereof, according to embodiments.
- FIG. 17 is a front view of an assembly including the locking mechanism and the primary plunger having a sealing member on the distal end thereof, according to embodiments.
- FIG. 18 is a side view of a secondary plunger of a dual-stage syringe, according to embodiments.
- FIG. 19 is a perspective view of a sleeved locking dual-stage syringe according to embodiments, in a shipment configuration.
- FIG. 20 is a perspective view of the sleeved locking dual-stage syringe of FIG. 16 , in a shipment configuration with primary plunger and locking mechanism visible through the external barrel.
- FIG. 21 is a longitudinal cross-section of the sleeved locking dual-stage syringe of FIGS. 19 and 20 in a shipment configuration.
- FIG. 22 is a perspective view of a sleeved locking dual-stage syringe according to embodiments, in a flushed configuration with primary plunger and locking mechanism visible through the external barrel.
- FIG. 23 is a longitudinal cross-section of the sleeved locking dual-stage syringe of FIG. 22 in a flushed configuration.
- FIG. 24 is a perspective view of a sleeved locking dual-stage syringe according to embodiments, in a punctured configuration with primary plunger and locking mechanism visible through the external barrel.
- FIG. 25 is a longitudinal cross-section of the sleeved locking dual-stage syringe of FIG. 23 in a punctured configuration.
- FIG. 26 is a cut-away view of a sleeved locking dual-stage syringe according to embodiments, in a primed configuration with primary plunger and locking mechanism visible through the external barrel.
- FIG. 27 is a longitudinal cross-section of the sleeved locking dual-stage syringe of FIG. 26 in a primed configuration.
- FIG. 28 is a perspective view of a sleeved locking dual-stage syringe according to embodiments, in a delivery configuration.
- FIG. 29 is a longitudinal cross-section of the sleeved locking dual-stage syringe of FIG. 28 in a delivery configuration.
- FIG. 30 is a side perspective view of a turn-key locking dual-stage syringe according to embodiments.
- FIG. 31 is a side perspective view of the secondary plunger and sealing member of the turn-key locking dual-stage syringe of FIG. 30 .
- FIG. 32 is a side perspective view of an assembly of the primary plunger, the secondary plunger, and the sealing member of the turn-key locking dual-stage syringe of FIG. 30 .
- FIG. 33 is a side cross section view of an integrated one-way valve syringe, according to embodiments.
- FIG. 34A is a side cross section view of the integrated one-way valve syringe of FIG. 33 in a first stage, according to embodiments.
- FIG. 34B is a side cross section view of the integrated one-way valve syringe of FIG. 33 in a second stage, according to embodiments.
- FIG. 34C is a side cross section view of the integrated one-way valve syringe of FIG. 33 in a third stage, according to embodiments.
- FIG. 35 is a side cross section view of an integrated one-way valve syringe according to embodiments.
- FIG. 36A is a side cross section view of the integrated one-way valve syringe of FIG. 35 in a first stage, according to embodiments.
- FIG. 36B is a side cross section view of the integrated one-way valve syringe of FIG. 35 in a second stage, according to embodiments.
- FIG. 36C is a side cross section view of the integrated one-way valve syringe of FIG. 35 in a third stage, according to embodiments.
- FIG. 37 is a schematic of a sleeved locking dual-stage syringe with membrane technology according to embodiments.
- FIG. 38 is a side view of a syringe with a ratcheting safety tab, according to embodiments.
- FIG. 39 is a side cross-section view of a syringe with a ratcheting safety tab, according to embodiments.
- FIG. 40A is top view of a telemeterized syringe plunger cap, according to embodiments.
- FIG. 40B is section view of a telemeterized syringe plunger cap, according to embodiments.
- FIG. 40C is a section view of a telemeterized syringe plunger cap assembled on a syringe plunger, according to embodiments.
- FIG. 41 is a schematic of a sleeved locking dual-stage syringe according to embodiments, incorporated into an example of a radioembolization delivery system for delivery of radioembolization bead solutions to a patient through a delivery catheter in fluidic communication with the sleeved locking dual-stage syringe.
- embodiments of the dual-stage syringes disclosed herein may be directed to locking-mechanism dual-stage syringes and dual-stage syringes having integrated one-way valves.
- embodiments of locking-mechanism dual-stage syringes may include sleeved dual-stage syringes.
- other embodiments of locking-mechanism dual-stage syringes may include turn-key dual-stage syringes.
- dual-stage syringes having one or more integrated one-way valves will be subsequently described in more detail.
- the dual-stage syringes may be incorporated into any system involving delivering or mixing multiple fluids including medical procedures involving delivery of multiple fluids such as therapeutic agents, flushing solutions, excipient solutions, isotonic sterile solutions, contrast agents, or combinations thereof.
- the dual-stage syringes may be incorporated into delivery systems for cancer treatments such as, for example, in delivery systems for chemotherapeutic agents or radiotherapeutic agents.
- the dual-stage syringes may be incorporated into delivery systems for chemoembolization therapy or radioembolization therapy, such as for fluids containing radioembolization beads that are mixed with one or more carrier solutions or contrast agents in preparation for being delivered to a patient in need of the therapy.
- the dual-stage syringes may be incorporated into delivery systems for transarterial radioembolization for tumor treatments such as, for example, liver-tumor treatments.
- distal means in the direction toward which a plunger is inserted into a barrel of the dual-stage syringes and in which a fluid is expelled from the dual-stage syringe during operation of the dual-stage syringe.
- proximal means opposite the direction toward which the plunger is inserted into a barrel of the dual-stage syringes and in which the fluid is expelled from the dual-stage syringe during operation of the dual-stage syringe.
- the locking-mechanism dual-stage syringes may include an external barrel, a primary plunger, and one or more locking mechanisms.
- the one or more locking mechanisms may be configured to define a first boundary, a second boundary, and at least three stages.
- the second boundary may be distal to the first boundary.
- the at least three stages may include an initial stage, an intermediate stage, and a final stage.
- the primary plunger is inserted proximal to the first boundary and may be freely movable distally or proximally.
- the intermediate stage the primary plunger is inserted distal to the first boundary and is prevented from moving proximally beyond the first boundary.
- the primary plunger is inserted distal to the second boundary and is prevented from moving proximally beyond the second boundary.
- the one or more locking mechanisms may be incorporated into the external barrel, the primary plunger, one or more additional components, or combinations thereof. In further embodiments, the one or more locking mechanisms may be incorporated as a feature on the surface of the external barrel, primary plunger, one or more additional components, or combinations thereof. Such features may be a male feature including one or more nibs, projections, protrusions, or combinations thereof. In embodiments, such features may be a female feature including one or more grooves, tracks, indentations, depressions, other surface modifications, or combinations thereof. In some embodiments, a male feature may have a corresponding female feature. In some embodiments, the one or more locking mechanisms may include a sleeved locking mechanism, a turn-key locking mechanism, or other locking mechanisms.
- a locking-mechanism dual-stage syringe 100 is provided according to embodiments.
- the locking-mechanism dual-stage syringe 100 may include an external barrel 10 , a primary plunger (piston) 50 , that accommodates a secondary plunger 70 .
- locking-mechanism dual-stage syringe 100 are depicted as aligned along a longitudinal axis 1 shared by the individual components 10 , 50 , 70 and the locking-mechanism dual-stage syringe 100 itself, when fully assembled.
- the locking-mechanism dual-stage syringe 100 may include an external barrel 10 .
- the external barrel 10 may have a primary chamber 90 defined through the external barrel 10 from a proximal opening of the external barrel 10 to a distal opening of the external barrel 10 .
- the external barrel 10 may be made of various materials such as, for example, polymers, plastics, or metals.
- Non-limiting example polymers for the external barrel include polycarbonates (PC), polyethylenes (PE), polyethylene terephthalates (PET).
- Non-limiting example plastics for the external barrel 10 include poly(methyl methacrylate) (PMMA) and composite resins such as polycarbonate loaded with tungsten.
- Non-limiting example metals and metal alloys for the external barrel 10 include stainless steel, titanium, copper, tungsten, aluminum, pewter, and various alloys of any of these.
- the external barrel 10 is made of a radiation shielding material such as the plastics or metals previously listed.
- the radiation shielding material may have a thickness sufficient to ensure that radiation from a radioactive therapeutic material in the dual-stage syringe having a one or more locking mechanisms 100 cannot penetrate to the environment or cause safety concerns for personnel operating the locking-mechanism dual-stage syringe 100 .
- suitable radiation shielding materials may shield operators of the dual-stage syringe having a sleeved locking mechanism 100 from beta-particle radiation, from x-rays, or both.
- the external barrel 10 of the locking-mechanism dual-stage syringe 100 may include an external proximal opening 11 , a proximal flared edge 13 around the external proximal opening 11 , an external distal opening 19 opposite the external proximal opening 11 , and a body portion 15 between the proximal flared edge 13 and the external distal opening 19 .
- the external barrel 10 may include a neck portion 17 between the body portion 15 and the external distal opening 19 .
- the external barrel 10 may optionally include a proximal depression 12 that may be configured to accommodate corresponding features of the primary plunger 50 , as described subsequently in greater detail.
- the external proximal opening 11 of the external barrel 10 may be sufficiently wide to accommodate the primary plunger 50 through the external proximal opening 11 .
- the external proximal opening 11 of the external barrel 10 may be sufficiently wide to accommodate a locking mechanism, such as a sleeved locking mechanism, through the external proximal opening 11 .
- the external barrel 10 has a primary chamber 90 defined therein.
- the primary plunger 50 may be insertable into primary chamber 90 .
- a locking mechanism may be insertable into primary chamber 90 .
- the external barrel 10 optionally may include gripping features 14 on a distal-facing side of the proximal flared edge 13 .
- the one or more locking mechanisms may be incorporated into the external barrel 10 .
- Male features may include, without limitation, nibs, projections, protrusions, or combinations thereof.
- Female features may include, without limitation, grooves, tracks, indentations, depressions, other surface modifications, and combinations thereof.
- the external barrel 10 may include one or more male features on the surface of the external barrel 10 .
- the one or more male features on the surface of the external barrel 10 may have corresponding one or more female features on the primary plunger 50 , one or more additional components, or combinations thereof.
- the external barrel 10 may include one or more female features on the surface of the external barrel 10 .
- the one or more female features on the surface of the external barrel 10 may have a corresponding one or more male features on the primary plunger, one or more additional components, or combinations thereof.
- the external barrel 10 may include a combination of male and female features on the surface of the external barrel 10 , which may have corresponding female and male features, respectively, on the primary plunger, one or more additional components, or combinations thereof.
- FIG. 5 shows an exemplary embodiment a locking-mechanism dual-stage syringe 100 having one or more locking mechanisms incorporated into the external barrel 410 .
- an external barrel 410 may include an initial-stage track 412 , an intermediate-stage track 414 , and a final-stage track 416 within the external barrel 410 .
- the initial-stage track 412 , the intermediate-stage track 414 , and the final-stage track 416 are all female features on the surface of external barrel 410 .
- indentations 418 are also female features on the surface of external barrel 410 .
- the initial-stage track 412 , the intermediate-stage track 414 , the final-stage track 416 , and the indentations 418 may be referred to as the female features of the locking mechanism of the embodiment illustrated in FIG. 5 .
- the female features of the locking mechanism of the embodiment illustrated in FIG. 5 have corresponding male features on the primary plunger of the embodiment illustrated in FIG. 5 .
- the male features and female features of the locking mechanism of the embodiment illustrated in FIG. 5 may be collectively referred to as the turn-key locking mechanism of the embodiment illustrated in FIG. 5 .
- the embodiment illustrated in FIG. 5 may also be referred to as a turn-key embodiment of the locking-mechanism dual-stage syringe 100 .
- the locking-mechanism dual-stage syringe 100 may include a turn-key locking mechanism that includes only the initial-stage track 412 , the intermediate-stage track 414 , and the final-stage track 416 but not the indentations 418 .
- the locking-mechanism dual-stage syringe 100 may include a turn-key locking mechanism that includes the initial-stage track 412 , the intermediate-stage track 414 , the final-stage track 416 , the indentations 418 , and one or more additional locking mechanisms.
- the intersection of the initial-stage track 412 with the intermediate-stage track 414 corresponds to an initial stage of the primary plunger.
- the primary plunger In the initial stage, the primary plunger is inserted proximal to the initial-stage track 412 and may be freely movable distally or proximally.
- the intermediate-stage track 414 corresponds to an intermediate stage of the primary plunger. In the intermediate stage, the primary plunger may traverse the intermediate-stage track and is prevented from moving proximally beyond the intermediate-stage track.
- the intersection of the final-stage track 416 with the intermediate-stage track 414 corresponds to a final stage of the primary plunger.
- the locking-mechanism dual-stage syringe 100 may include a turn-key locking mechanism that includes one or more additional tracks in the surface of the external barrel 410 , which may define one or more additional stages.
- the external barrel 410 may include any of the polymers, plastics, metals, or alloys listed previously, or it may include other materials, such as nylon.
- the primary plunger 50 may have a secondary chamber defined through the primary plunger 50 from a proximal opening of the primary plunger 50 to a sealed distal end of the primary plunger 50 , the primary plunger 50 configured to receive a secondary plunger (piston) 70 through the proximal opening of the primary plunger 50 .
- the primary plunger 50 may be sufficiently narrow to be accommodated by external barrel 10 .
- the primary plunger 50 may be made of various materials such as, for example, polymers, plastics, or metals.
- Non-limiting example polymers for the external barrel include polycarbonates (PC), polyethylenes (PE), polyethylene terephthalates (PET).
- Non-limiting example plastics for the primary plunger 50 include poly(methyl methacrylate) (PMMA) and composite resins such as polycarbonate loaded with tungsten.
- Non-limiting example metals and metal alloys for the primary plunger 50 include stainless steel, lead, copper, tungsten, aluminum, pewter, and various alloys of any of these.
- the primary plunger 50 is made of a radiation shielding material such as the plastics or metals previously listed.
- the radiation shielding material may have a thickness sufficient to ensure that radiation from a radioactive therapeutic material in the dual-stage syringe having a one or more locking mechanisms 100 cannot penetrate to the environment or cause safety concerns for personnel operating the locking-mechanism dual-stage syringe 100 .
- suitable radiation shielding materials may shield operators of the dual-stage syringe having a sleeved locking mechanism 100 from beta-particle radiation, from x-rays, or both.
- the primary plunger 50 may include a proximal wing portion 51 , a distal plunger opening 53 , and a plunger body portion 55 .
- the primary plunger may include a secondary chamber 95 defined therein from the proximal wing portion 51 to the distal plunger opening 53 .
- the primary plunger 50 optionally may include handle-locking features 52 on the proximal wing portion 51 .
- the secondary chamber 95 may accommodate the secondary plunger 70 , which will be described subsequently in more detail.
- the plunger body portion 55 may include one or more stop rings such as a distal stop ring 56 and a proximal stop ring 58 . In some embodiments, both the distal stop ring 56 and the proximal stop ring 58 may be configured to interact with embodiments of a locking mechanism, subsequently described in more detail, as the primary plunger 50 is moved.
- the primary plunger 50 may include a seal seat 59 for mounting a plunger seal 60 .
- the plunger seal 60 may include one-way valves, flaps, or flow channels.
- the plunger seal 60 may be mounted on the primary plunger, such that the plunger seal 60 covers the distal plunger opening 53 to prevent fluidic flow through the distal plunger opening 53 until an appropriate stage in the operation of the locking-mechanism dual-stage syringe 100 , as will be described in greater detail.
- one or more locking mechanisms may be incorporated into the primary plunger.
- the one or more locking mechanisms incorporated into the primary plunger may include one or more features on the surface of the primary plunger, such as male features and/or female features.
- Male features may include, without limitation, nibs, projections, protrusions, or combinations thereof.
- Female features may include, without limitation, grooves, tracks, indentations, depressions, other surface modifications, and combinations thereof.
- the primary plunger 50 may include one or more male features on the surface of the primary plunger 50 .
- the one or more male features on the surface of the primary plunger 50 may have corresponding one or more female features on the external barrel, one or more additional components, or combinations thereof.
- the primary plunger 50 may include one or more female features on the surface of the primary plunger 50 .
- the one or more female features on the surface of the primary plunger 50 may have a corresponding one or more male features on the external barrel, one or more additional components, or combinations thereof.
- the primary plunger 50 may include a combination of male and female features on the surface of the primary plunger 50 , which may have corresponding female and male features, respectively, on the external barrel, one or more additional components, or combinations thereof.
- FIG. 10 shows an exemplary embodiment of a locking-mechanism dual-stage syringe incorporated into the primary plunger.
- a primary plunger 450 includes male features (nibs) 465 , which are shaped and sized appropriately to correspond the female features of the turn-key locking mechanism of FIG. 5 , previously described.
- male features the may be shaped and sized appropriately to travel within the tracks 412 , 414 , 416 of the external barrel 410 .
- the one or more locking mechanisms of the locking-mechanism dual-stage syringe 100 may be configured to define a first boundary, a second boundary, and at least three stages.
- the second boundary may be distal to the first boundary.
- the at least three stages may include an initial stage, an intermediate stage, and a final stage.
- the primary plunger is inserted proximal to the first boundary and may be freely movable distally or proximally.
- the primary plunger is inserted distal to the first boundary and is prevented from moving proximally beyond the first boundary.
- the primary plunger is inserted distal to the second boundary and is prevented from moving proximally beyond the second boundary.
- the one or more locking mechanisms may be incorporated into a sleeve disposed within the primary chamber 90 .
- the one or more locking mechanisms incorporated into a sleeve disposed within the primary chamber 90 may include a feature on the surface of the sleeve disposed within the primary chamber 90 such as a nib, projection, protrusion, groove, track, indentation, or other surface modification.
- An example of a locking mechanism incorporated into a sleeve disposed within the primary chamber 90 may include a sleeved locking mechanism, which will now be described in greater detail.
- a dual-stage syringe having a sleeved locking mechanism 200 may include an external barrel 210 , a locking sleeve 230 , and a primary plunger 250 that accommodates a secondary plunger 270 .
- a primary plunger 250 that accommodates a secondary plunger 270 .
- the components of the dual-stage syringe having a sleeved locking mechanism 300 are depicted as aligned along a longitudinal axis 31 shared by the individual components 210 , 230 , 250 , 270 and the dual-stage syringe having a sleeved locking mechanism 200 itself, when fully assembled.
- the locking sleeve 230 is accommodated within the external barrel 210
- at least a portion of the primary plunger 250 is accommodated within the locking sleeve 230 and the external barrel 210
- at least a portion of the secondary plunger 270 may be accommodated within the primary plunger 250 .
- embodiments of the dual-stage syringe having a sleeved locking mechanism 200 may include a locking sleeve 230 .
- the locking mechanism 230 may include a body portion 235 having a shape conforming to contours of the external barrel 10 .
- the locking mechanism 230 may include one or more features that can be used for integrational assembly, such as a proximal ridge 232 configured to seat the locking mechanism in the external proximal opening 11 of the external barrel 10 .
- the locking mechanism 230 may include distal catch members 240 .
- the distal catch members 240 may have various shapes and dimensions suited to perform a locking function, as will be described subsequently in greater detail.
- the distal catch members 240 may have sufficient resilience to permit the primary plunger 50 to pass through the locking mechanism in a distal direction, but to deflect outwardly and prevent proximal movement of the primary plunger 50 , as will be described.
- the distal catch members 240 are configured as long catches 242 and short catches 246 alternating around the circumference of the body portion 235 at the distal end of the body portion 235 .
- the long catches 242 include long-catch ends 244 angled slightly inwardly (i.e., toward the longitudinal axis 1 (see FIG. 11 )) of the sleeved locking dual-stage syringe 200 .
- the short catches 246 include short-catch ends 248 also angled slightly inwardly.
- the lengths of the long catches 242 define a distal stop level 243 .
- the lengths of the short catches 246 define a proximal stop level 247 .
- the distal stop level 243 and the proximal stop level 247 define positions, beyond which when the primary plunger 50 is inserted into the external barrel 10 and surrounded by the locking mechanism 30 , proximal movement of the primary plunger 50 is prevented.
- the primary plunger 250 is insertable into the locking sleeve 230 .
- the distal stop ring 256 and, subsequently, the proximal stop ring 258 passes distally beyond the distal catch members 340 (for example, the long catches 342 and the short catches 346 ).
- the distal catch members 340 then deflect inwardly, in turn locking the primary plunger 350 in a manner that prevents proximal withdrawal of the primary plunger 350 beyond a point at which the proximal stop ring 358 would pass in a proximal direction back through the distal catch members 340 (i.e., beyond the long-catch ends 44 ).
- the distal catch members 240 may be catches of varying lengths around the circumference of the body portion 235 at the distal end of the body portion 235 .
- the long catches 242 include long-catch ends 244 that may be angled slightly outwardly (i.e., away from the longitudinal axis 1 (see FIG. 11 )) of the sleeved locking dual-stage syringe 200 .
- the short catches 246 include short-catch ends 248 that may be angled slightly outwardly.
- the secondary plunger 70 may include an elongated portion 74 , a handle portion 75 , and a secondary seal 80 .
- the elongated portion 74 of the secondary plunger 70 may include ribbed members 76 perpendicular to the elongated portion 74 to provide stability to the elongated portion 74 and facilitate insertion of the secondary plunger 70 into the secondary chamber 95 of the primary plunger 50 .
- the secondary plunger 70 may include an insertion stop 72 that defines a maximum extent to which the secondary plunger 70 may be inserted into the secondary chamber 95 of the primary plunger 50 . It should be understood that the insertion stop 72 , the elongated portion 74 , the handle portion 75 , and ribbed members 76 (if any), may have various shapes, sizes, or configurations and are not limited to the specific configuration of FIG. 18 .
- the primary components of the dual-stage syringes having sleeved locking mechanisms 200 have been described, along with general operating principles of the locking sleeve 230 .
- the primary components and the general operating principles result in at least five operational stages of the dual-stage syringes having sleeved locking mechanisms 200 , each of which now will be described with reference to FIGS. 19-29 .
- the operational stages include a shipped configuration ( FIGS. 19-21 ), a flushed configuration ( FIGS. 22-23 ), a punctured configuration ( FIGS. 24-25 ), a primed configuration ( FIGS. 26-27 ), and a delivery configuration ( FIGS. 28-29 ).
- the shipped configuration of FIGS. 19-21 of the sleeved locking dual-stage syringe 200 is a configuration in which the sleeved locking dual-stage syringe 200 may be received by a qualified medical practitioner intending to incorporate the sleeved locking dual-stage syringe 200 into a delivery system for a procedure such as radioembolization.
- the locking mechanism 230 , the primary plunger 250 , and the secondary plunger 270 all are inserted to varying extents into the external barrel 210 .
- the locking mechanism 230 is fully inserted into the external barrel 210 so that the proximal ridge 232 is seated in the external proximal opening 211 of the external barrel 210 .
- the primary plunger 250 is only partially inserted into the external barrel 210 , such that some amount of the plunger body portion 255 remains outside the external barrel 210 .
- the primary plunger 250 is inserted only sufficiently far through the locking mechanism, such that the distal stop ring 256 has not passed distally beyond the long-catch ends 244 of the long catches 242 of the locking mechanism 230 .
- the portion of the primary chamber 290 not filled by the primary plunger 250 initially contains a fluid such as saline, which fluid is intended to flush the system of air at the beginning of the radioembolization procedure.
- a delivery needle 150 is shown as protruding into the primary chamber 290 .
- the delivery needle 150 may be attached to the sleeved locking dual-stage syringe 200 in the shipped configuration.
- the delivery needle 150 may be a component of a delivery system.
- Some embodiments may include a distal fixture 5 .
- distal feature 5 may be a gasket, which seals the external distal opening 217 of the external barrel 210 to prevent fluidic communication between the primary chamber 290 and the outside of the external barrel 210 , except through the delivery needle 150 .
- distal feature 5 may be a luer connection, which may be used to connect a the locking dual-stage syringe 200 to a delivery device.
- the luer connection may be a male luer connection that has a corresponding female luer connection on a delivery device.
- the distal feature 5 may be another connection feature, such as a slip fit, a needless connection port, or any other connection suitable for attachment to a delivery device.
- the secondary plunger 270 is inserted into the secondary chamber 295 to such an extent that the insertion stop 272 abuts the proximal wing portion 251 of the primary plunger 250 .
- the portion of the secondary chamber 295 that is not occupied by the secondary plunger 270 is filled with radioembolization beads (not shown).
- the radioembolization beads are sealed within the secondary chamber by the plunger seal 260 . No fluidic communication exists between the primary chamber 290 and the secondary chamber 295 .
- the practitioner may pull the secondary plunger 270 proximally to cause both the primary plunger 250 and the secondary plunger 70 to move proximally, thereby expanding the primary chamber 290 and drawing the fluid in the reservoir into the primary chamber 290 by suction force. The practitioner may then push the secondary plunger distally to force the fluid in the primary chamber 290 back toward the reservoir and place the sleeved locking dual-stage syringe 200 into the flushed configuration.
- the proximal stop ring 258 in the flushed configuration of FIGS. 22-23 of the sleeved locking dual-stage syringe 200 , the proximal stop ring 258 has passed the short-catch ends 248 and is substantially even with the long-catch ends 244 but has not passed the long-catch ends 244 in a distal direction.
- the short-catch ends 248 may snap inwardly with an audible click to inform the practitioner that the flushed configuration has been reached. Once the audible click has been heard, the primary plunger cannot move proximally beyond the point at which the short-catch ends 48 abut against the proximal stop ring 258 .
- the delivery needle 150 has not pierced through the plunger seal 260 of the primary plunger 250 .
- sleeved locking dual-stage syringe 200 reaches the punctured configuration so that mixing of the radioembolization beads in the secondary chamber 295 of the primary plunger 250 with fluids forced into the reservoir of the delivery system may commence.
- the primary plunger 250 has been inserted to its fullest extent into the external barrel 210 , whereby the delivery needle 150 pierces through the plunger seal 260 and a piercing end 155 of the delivery needle 150 is disposed within the secondary chamber 295 containing the radioembolization beads. Furthermore, as the punctured configuration is reached, the proximal stop ring 258 passes the long-catch ends 244 of the locking mechanism 230 .
- the long-catch ends 244 deflect inwardly by their resilience, resulting in a second audible click to inform the practitioner that the punctured configuration has been reached and the secondary chamber 295 is in fluidic communication with the reservoir of the delivery system outside the sleeved locking dual-stage syringe 100 . Accordingly, the primary plunger 250 is locked a second time and proximal movement of the primary plunger 250 is completely prevented.
- the practitioner may unlock the secondary plunger 270 , for example, by rotating the secondary plunger 270 .
- the practitioner then may pull the secondary plunger 270 in the proximal direction to expand the secondary chamber 295 and draw fluid from the reservoir of the delivery system into the secondary chamber 295 to be intimately mixed with the radioembolization beads in the secondary chamber 295 .
- the secondary plunger 270 is pulled proximally to its maximum extent, without removing the secondary plunger 270 from the secondary chamber 295 , the sleeved locking dual-stage syringe 200 is in the primed configuration.
- the secondary chamber 295 has its maximum volume and contains a treatment mixture such as a mixture of radioembolization beads, for example and an appropriate carrier fluid such as saline, for example. This mixture is the delivery mixture, ready for injection into the patient.
- a treatment mixture such as a mixture of radioembolization beads, for example and an appropriate carrier fluid such as saline, for example.
- This mixture is the delivery mixture, ready for injection into the patient.
- the practitioner pushes the secondary plunger 270 in the distal direction to expel the delivery mixture, created when the sleeved locking dual-stage syringe 200 was placed into the primed configuration previously described, distally through the delivery needle 150 and into a delivery system for injection into the patient.
- the abutting of the insertion stop 272 of the secondary plunger 270 against the proximal wing portion 251 of the primary plunger 250 signals to the practitioner that the secondary plunger 270 has been fully depressed and the dosing of the delivery mixture is complete.
- the practitioner may pump the secondary plunger 270 multiple times to accomplish multiple cycles of refilling the secondary chamber 295 with fluid and expelling the contents of the secondary chamber 295 , so as to ensure that the full dosing of the radioembolization beads has been sent to the delivery system.
- FIGS. 30-32 Individual components of an embodiment of a turn-key locking dual-stage syringe 400 have previously been described, including the external barrel 410 and the primary plunger 450 .
- an exemplary embodiment of the turn-key locking dual-stage syringe 400 fully assembled includes an external barrel 410 , a primary plunger 450 (accommodated within the external barrel 410 ), and a secondary plunger 470 .
- the turn-key locking dual-stage syringe 400 includes a turn-key locking mechanism.
- the turn key locking mechanism may include an initial-stage track 412 , a intermediate-stage track 414 , and a final-stage track 416 within the external barrel 410 .
- the turn-key locking dual-stage syringe 400 may include one or more additional tracks Like the sleeved locking dual-stage syringe 200 previously described, the turn-key locking dual-stage syringe 400 may include any of the polymers, plastics, metals, or alloys listed above, or it may include other materials such as nylon.
- a primary plunger 450 includes male features 465 , which are shaped and sized appropriately to correspond the female features of the turn-key locking mechanism of FIG. 5 , previously described.
- male features 465 may be shaped and sized appropriately to travel within the tracks 412 , 414 , 416 of the external barrel 410 .
- the intersection of the initial-stage track 412 with the 414 corresponds to an initial stage of the primary plunger.
- the intersection of the initial-stage track 412 with the intermediate-stage track 414 corresponds to a position of the primary plunger 450 analogous to the flushed configuration of the sleeved locking dual-stage syringe 200 , described previously.
- the primary plunger is inserted proximal to the initial-stage track 412 and may be freely movable distally or proximally.
- the intermediate-stage track 414 corresponds to an intermediate stage of the primary plunger. In the intermediate stage, the primary plunger may traverse the intermediate-stage track and is prevented from moving proximally beyond the intermediate-stage track.
- the physician rotates the secondary plunger 470 to shift the male features 465 across the intermediate-stage track 414 and prepare the turn-key locking dual-stage syringe 400 to enter the delivery configuration.
- the intersection of the final-stage track 416 with the intermediate-stage track 414 corresponds to a final stage of the primary plunger.
- a final push of the secondary plunger 470 in a distal direction causes the male features 465 to slide down the final-stage track 416 sufficiently far to cause a delivery needle to pierce the secondary seal 80 of the primary plunger 450 .
- the primary plunger is inserted distal to the intermediate-stage track and is prevented from moving proximally beyond a distal end of the final-stage track.
- the turn-key locking dual-stage syringe 400 may include a turn-key locking mechanism that includes one or more additional tracks in the surface of the external barrel 410 , which may define one or more additional stages.
- the dual-stage syringes described herein include integrated one-way valve dual-stage syringe.
- the integrated one-way valve dual-stage syringe may be a dual-stage syringe having an integrated one way valve and needle. and needle.
- the integrated one-way valve dual-stage syringe may be a dual-stage syringe having two integrated one way valves.
- Embodiments of the integrated one-way valve dual-stage syringe may be used in any technical setting where it is necessary to delivery two separate and isolated mediums, such as during Transarterial Radioembolization for the treatment of malignant liver tumors.
- the integrated one-way valve dual-stage syringe 600 may include a primary plunger 650 , which may be configured to deliver at least two media independently.
- the integrated one-way valve dual-stage syringe 600 may include an external barrel 610 , which accommodates a primary plunger 650 .
- the external barrel 610 may have a primary chamber 690 defined through the external barrel 610 from a proximal opening of the external barrel 610 to a distal opening 619 of the external barrel 610 .
- a floating septum plunger 674 may be disposed within the primary chamber 690 of the external barrel 610 .
- a divider 672 may be disposed within the primary chamber 690 of the external barrel 610 , which divides the secondary chamber 606 to the primary chamber 690 .
- the external barrel 610 may be made of various materials such as, for example, polymers, plastics, or metals.
- Non-limiting example polymers for the external barrel include polycarbonates (PC), polyethylenes (PE), polyethylene terephthalates (PET).
- Non-limiting example plastics for the external barrel 610 include poly(methyl methacrylate) (PMMA) and composite resins such as polycarbonate loaded with tungsten.
- Non-limiting example metals and metal alloys for the external barrel 610 include stainless steel, lead, copper, tungsten, aluminum, pewter, and various alloys of any of these.
- the external barrel 610 is made of a radiation shielding material such as the plastics or metals previously listed.
- the radiation shielding material may have a thickness sufficient to ensure that radiation from a radioactive therapeutic material in the integrated one-way valve dual-stage syringe 600 cannot penetrate to the environment or cause safety concerns for personnel operating the integrated one-way valve dual-stage syringe 600 .
- suitable radiation shielding materials may shield operators of the integrated one-way valve dual-stage syringe 600 from beta-particle radiation, from x-rays, or both.
- the external barrel 610 may include an external proximal opening 611 , an external distal opening 619 opposite the external proximal opening 611 , and a body portion 615 between the external proximal opening 611 and the external distal opening 619 .
- the integrated one-way valve dual-stage syringe 600 may include one or more locking mechanisms, such as those described previously.
- the integrated one-way valve dual-stage syringe 600 may include a locking sleeve.
- An example of an integrated one-way valve dual-stage syringe 600 that includes a locking sleeve 630 is provided in FIGS. 33 and 36 .
- Locking sleeve 630 may be similar to locking sleeve 230 .
- locking sleeve 630 which may include distal catch members are configured as long catches and short catches alternating around the circumference of the body portion at the distal end of the locking sleeve 630 .
- the one or more locking mechanisms 630 may allow for greater delivery control and may provide tactile and audio feedback for assurance of when media are changed.
- the locking mechanisms of the integrated one-way valve dual-stage syringe 600 may be temporary or permanent.
- the integrated one-way valve dual-stage syringe 600 may include a primary plunger 650 of the locking-mechanism dual-stage syringe 100 .
- the primary plunger 650 may have a sealed distal end 604 that defines a secondary chamber 606 .
- the primary plunger 650 may be sufficiently narrow to be accommodated by external barrel 610 .
- the primary plunger 650 is may engage the secondary chamber 606 and cause the secondary chamber 606 to function as a plunger to the external barrel 610 . This may assure that little or no pressure may be applied to the medium in the secondary chamber 606 during the actuation of the external barrel 610 .
- the primary plunger 650 may be made of various materials such as, for example, polymers, plastics, or metals.
- Non-limiting example polymers for the external barrel include polycarbonates (PC), polyethylenes (PE), polyethylene terephthalates (PET).
- Non-limiting example plastics for the primary plunger 650 include poly(methyl methacrylate) (PMMA) and composite resins such as polycarbonate loaded with tungsten.
- Non-limiting example metals and metal alloys for the primary plunger 650 include stainless steel, lead, copper, tungsten, aluminum, pewter, and various alloys of any of these.
- the primary plunger 650 is made of a radiation shielding material such as the plastics or metals previously listed.
- the radiation shielding material may have a thickness sufficient to ensure that radiation from a radioactive therapeutic material in the integrated one-way valve dual-stage syringe 600 cannot penetrate to the environment or cause safety concerns for personnel operating integrated one-way valve dual-stage syringe 600 .
- suitable radiation shielding materials may shield operators of the integrated one-way valve dual-stage syringe 600 from beta-particle radiation, from x-rays, or both.
- Embodiments of the integrated one-way valve dual-stage syringe 600 may include a one-way valve 682 , which is configured to allow flow in only one direction, which may be from the secondary chamber 606 to the primary chamber 690 .
- One-way valve 682 may allow for a medium in a secondary chamber 606 to be mixed with fluid from the primary chamber 690 .
- the integrated one-way valve dual-stage syringe 600 may allow for a medium in a secondary chamber 606 to be mixed with fluid from the primary chamber 690 multiple times and for the primary chamber 690 to be purged multiple times.
- the integrated one-way valve dual-stage syringe 600 may include one or more additional one-way valves, which are each configured to allow flow in only one direction.
- the one-way valves may allow for a flow path that mixes the media contained in the primary chamber 690 with the media in the secondary chamber 606 while eliminating the need for secondary or external connections, such as secondary or external connections with one or more additional syringes.
- the number and sizes of the chambers can vary.
- the integrated one-way valve dual-stage syringe 600 may include and a needle 150 that passes through the floating septum plunger 674 and into the primary chamber 690 .
- This embodiment may include a one way valve 681 at the distal end of the needle 150 .
- the divider 672 may include a port 673 .
- the port 673 may be aligned with the needle 150 .
- the primary plunger 650 , the external barrel 610 , or other component may be rotated in order to align the port 673 with the needle 150 .
- FIGS. 34A, 34B, and 34C exemplify operation of the embodiment of the integrated one-way valve dual-stage syringe 600 FIG. 33 .
- the primary plunger 650 is advanced distally, which advances the secondary chamber 606 and sealed distal end 604 distally.
- a first lock of the locking sleeve 630 may be engaged, and the barrel may be rotated to engage a second lock of the locking sleeve 630 and align the needle 150 and the sealed port 673 .
- FIG. 34C a second lock of the locking sleeve 630 may be engaged, and the needle 150 may puncture the port 673 .
- FIG. 34A the primary plunger 650 is advanced distally, which advances the secondary chamber 606 and sealed distal end 604 distally.
- a first lock of the locking sleeve 630 may be engaged, and the barrel may be rotated to engage a second lock of the locking sleeve 630 and align the needle 150 and the sealed
- media from the primary chamber 690 may flow from the primary chamber 690 through the one-way valve 682 , into the secondary chamber 606 to be mixed with fluid from the primary chamber 690 .
- the mixed fluid may then flow through the port 673 through the hollow needle 150 , through the one way valve 681 , and out the external distal opening 619 .
- the integrated one-way valve dual-stage syringe 600 may include a one-way valve 683 on one side of the external barrel 610 , which may be allow flow from the secondary chamber 606 to a channel 627 disposed within the sidewall 629 of the external barrel 610 .
- FIGS. 36A, 36B, and 36C exemplify operation of the embodiment of the integrated one-way valve dual-stage syringe 600 FIG. 35 .
- the primary plunger 650 is advanced distally, which advances the secondary chamber 606 and sealed distal end 604 distally.
- a first lock of the locking sleeve 630 may be engaged, and the barrel may be rotated to engage a second lock of the locking sleeve 630 and align an opening 677 (see FIG. 35 ) with the one-way valve 683 .
- FIG. 35A the primary plunger 650 is advanced distally, which advances the secondary chamber 606 and sealed distal end 604 distally.
- a first lock of the locking sleeve 630 may be engaged, and the barrel may be rotated to engage a second lock of the locking sleeve 630 and align an opening 677 (see FIG. 35 ) with the one-way valve 683 .
- FIG. 35A the primary plunger 650
- a second lock of the locking sleeve 630 may be engaged, and the one-way valve 683 may be aligned so that the secondary chamber 606 is in fluid communication the channel 627 disposed within the sidewall 629 of the external barrel 610 .
- media from the primary chamber 690 may flow from the primary chamber 690 through the one-way valve 682 , into the secondary chamber 606 to be mixed with fluid from the primary chamber 690 .
- the mixed fluid may then flow through the one-way valve 683 , through the channel 627 through the one way valve 681 , and out the external distal opening 619 .
- the integrated one-way valve dual-stage syringe 600 comprise any biocompatible material such as metals, metal alloys, and polymers.
- the integrated one-way valve dual-stage syringe 600 may include polymers such as polycarbonate, polyethylene, and polyethylene terephthalate.
- the integrated one-way valve dual-stage syringe 600 may include seals made from any suitable material, such as thermoplastic elastomers, thermoplastic vulcanizates, silicone.
- the integrated one-way valve dual-stage syringe 600 may include metals, such as lead, stainless steel, and copper.
- the integrated one-way valve dual-stage syringe 600 may be overmolded a material such as thermoplastic elastomers, thermoplastic vulcanizates, or silicone, for example.
- the one or more safety features may include a distal feature 5 (see FIG. 21 ), such a gasket, luer connection, slip fit, a needless connection port, or any other connection suitable for attachment to a delivery device.
- a distal feature 5 such as a gasket, luer connection, slip fit, a needless connection port, or any other connection suitable for attachment to a delivery device.
- embodiments of the dual-stages syringes described herein, which may include locking-mechanism dual-stage syringes and dual-stage syringes having integrated one-way valves may include a gasket similar to distal feature 5 of FIG.
- the dual-stages syringes described herein which may include locking-mechanism dual-stage syringes and dual-stage syringes having integrated one-way valves, may include a luer connection, similar to distal feature 5 (see FIG. 21 ), which may be used for connection to a delivery device.
- the luer connection may be a male luer connection that has a corresponding female luer connection on a delivery device.
- the distal feature 5 may be another connection feature, such as a slip fit, a needless connection port, or any other connection suitable for attachment to a delivery device.
- the dual-stage syringes described herein may include one or more safety features, which may contribute to making embodiments of the dual-stage syringes describe herein suitable for safe and effective delivery of hazardous therapeutic materials.
- safety features that may be optionally incorporated into embodiments of the dual-stage syringes described herein may include membrane technology, safety tabs, telemeterized syringe plunger caps, needle features, magnetic walls, and combinations thereof.
- the distal end 19 may be sealed with a removeable or puncturable material.
- the distal end 419 (see FIG. 5 ) and the distal end 610 (see FIGS. 33, 35 ) may be sealed with a removeable or puncturable material.
- the one or more safety features may include a relief valve or vent, which may serve to relieve pressure from within the syringe, for example, when the primary plunger is distally advanced.
- the relief valve or vent 3 may be integrated into the distal end of the external barrel, as shown in FIG. 21 .
- the dual-stage syringe may optionally include membrane technology 800 to facilitate purging of air from the system.
- an exemplary embodiment includes a sleeved locking dual-stage syringe 200 in the punctured configuration in fluidic communication with membrane technology 800 .
- the membrane technology 800 may include components that work together to form dry, leakproof connections, airtight expansion chambers that reduce surface contamination and prevent microbial ingress.
- the membrane technology components may be adapted to standards that are compatible with all standard sizes of hazardous drug vials and intravenous connections and tubing.
- the dual-stage syringe may optionally include a ratcheting safety tab 900 to help mix or suspend pharmaceuticals and particles in a defined volume of solution.
- radioactive particles such as microspheres
- a medical facility in a prefilled syringe, such as embodiments of the dual-stages syringes described herein.
- the radioactive particles may settle at the bottom of the syringe. Therefore, it is required for the medical professional to draw up a given amount of saline into the syringe to help re-suspend the particles so that the therapeutic fluid comprising the particles has the appropriate concentration for effective delivery. If this suspension is not performed, there may be a risk of the particles either being delivered in a large bolus to the patient and/or there is a risk that the large bolus may clog the administrative tubing set, which may result in misadministration.
- a ratcheting safety tab 900 may be incorporated into embodiments of the dual-stages syringes described herein to help mix or suspend pharmaceuticals and particles in a defined volume of solution.
- a ratcheting safety tab 900 may include a safety tab 910 , connected at one end of safety tab 910 to the primary plunger 50 by a plunger attachment portion 940 , which may include one or more angled teeth 920 at the distal end 930 of the ratcheting safety tab 900 .
- FIG. 39 illustrates a cross-sectional side view of a ratcheting safety tab 900 configured to an embodiments of the dual-stages syringes described herein.
- the one or more angled teeth 920 may engage one or more retention clips attached to the primary plunger 50 .
- various mating mechanisms could be used, such as pins and lots, which may engage one or more retention clips attached to the primary plunger 50 .
- the primary plunger 50 may be pulled proximally, until each of the one or more angled teeth 920 on the safety tab 910 slide past the retention clip 11 .
- the geometry may be of any configuration such that primary plunger 50 must be pulled a predetermined distance before the safety tab safety tab 910 may be removed.
- the primary plunger 50 may then be depressed, and the treatment may be administered. In other embodiments, the safety tab 910 may not need to be removed from the primary plunger 50 for the treatment to be administered. Once the primary plunger 50 is pulled beyond the predetermined distance, the user could rotate the safety tab 910 to an “unlocked” or “delivery” position. Once the safety tab 910 is unlocked, the primary plunger 50 may then be depressed, and the treatment may be administered. When the safety tab 910 is locked, the primary plunger 50 cannot be depressed, and the treatment cannot be administered.
- the ratcheting safety tab 900 may include any biocompatible material such as metals, metal alloys, and polymers.
- the ratcheting safety tab 900 may include polymers such as polycarbonate, polyethylene, polypropylene and polyethylene terephthalate.
- the ratcheting safety tab 900 may include seals made from any suitable material such as thermoplastic elastomers, thermoplastic vulcanizates, or silicone, for example.
- the ratcheting safety tab 900 may include metals, such as lead, aluminum, stainless steel, and copper.
- the dual-stage syringes described herein may include a telemeterized syringe plunger cap 1000 .
- liver cancer can be treated with embolizing beads in conjunction with chemotherapy.
- embolizing beads in conjunction with chemotherapy.
- the vasculature has been structurally wakened from chemotherapy.
- the injection pressure the physician can safely use may be limited.
- the efficacy and dispersion of embolizing beads is correlated with increased injection pressure and flow rates.
- the dual-stage syringes described herein may include a telemeterized syringe plunger cap 1000 , which may monitor and record the injection pressure and flow rate of the embolizing beads delivered from the dual-stage syringe and allow for the desired dispersion to be achieved without damaging the vasculature.
- a telemeterized syringe plunger cap may provide real-time feedback to the medical professional, and the resulting data could be correlated to patience outcomes, serve for quantitate training, and provide inputs to automated systems and ergonomic devices.
- one or more of a pressure sensor and/or a displacement sensor of a telemeterized syringe plunger cap may sense a corresponding movement of the syringe plunger as a sensed plunger movement; when the syringe plunger is translationally moved in a translational direction, such that movement in the translational direction one of proximally or distally advances the syringe plunger. In embodiments, this then generates via the one or more of a pressure sensor and a displacement sensor of the telemeterized syringe plunger cap, one or more output signals based on the sensed plunger movement.
- at least one of the flow rate of the administered fluid, the flow amount of the administered fluid, the pressure of the administered fluid, or the translational direction of movement of the syringe plunger with respect to the syringe may be displayed on a display communicatively coupled to the syringe.
- FIG. 40A shows a top view of a telemeterized syringe plunger cap 1000 .
- the telemetered syringe plunger cap 1000 may include a wireless transmitter 1008 , a pressure sensor 1005 and displacement sensor 1001 housed in a cap that attaches to the proximal end of a plunger or a syringe 100 .
- FIG. 40B shows a section view along A-A shown in FIG. 40A .
- FIG. 40C shows the telemeterized syringe plunger cap 1000 attached to the proximal end of a plunger or a syringe 100 .
- the mechanism for engagement between the telemeterized syringe plunger cap 1000 and the syringe 100 may be, for example, mechanical, chemical, or magnetic.
- the wireless transmitter 1008 may be a Bluetooth transmitter.
- the displacement sensor 1001 may include an accelerometer.
- the cap may be made from polyethylene.
- the telemeterized syringe plunger cap 1000 may be attached to the proximal end of a plunger or a syringe 100 that contains radioactive materials, such as microspheres.
- the physician applies pressure to the top of the syringe, the telemeterized syringe plunger cap 1000 will deflect, and the pressure will be measured by the internal pressure sensor 1005 .
- the displacement sensor 1001 will register the motion.
- the information from both the pressure sensor 1005 and the displacement sensor 1001 may be wirelessly transmitted in real time to a computer or smart device where the information may be viewed and stored.
- the telemeterized syringe plunger cap 1000 may be discarded or recovered for sterilization and reuse.
- the telemeterized syringe plunger cap 1000 may communicate with other devices by various communication means including Bluetooth, WiFi, and wired connections.
- the telemeterized syringe plunger cap 1000 may include any number of sensors of varying types, such as capacitance sensors, resistance sensors, laser sensors, and optical sensors, which may produce the same outputs previously described. In other embodiments, the telemeterized syringe plunger cap 1000 may include any number of sensors of varying types, such as RFID tags and temperature sensors, which may produce additional outputs or labeling. In some embodiments, additional sensors may be added to monitor withdraw forces, pressures, or rates.
- the telemeterized syringe plunger cap 1000 may include different display modalities, such as LED, projection, and tactile display modalities. In other embodiments, the telemeterized syringe plunger cap 1000 may include alarm features, such as flashing lights, sounds, vibrations.
- the telemeterized syringe plunger cap 1000 may include any biocompatible material such as metals, metal alloys, and polymers.
- the telemeterized syringe plunger cap 1000 may include polymers such as polycarbonate, polyethylene, polypropylene and polyethylene terephthalate.
- the telemeterized syringe plunger cap 1000 may include seals made from any suitable material such as thermoplastic elastomers, thermoplastic vulcanizates, silicone.
- the telemeterized syringe plunger cap 1000 may include polyoxymethylene and acrylonitrile butadiene styrene.
- the telemeterized syringe plunger cap 1000 may include metals, such as lead, aluminum, stainless steel, and copper.
- the external barrel 10 of embodiments of the dual-stage syringes described herein may include one or more needles that may be attached to or mounted on the external barrel near the external distal opening 19 of the external barrel 10 .
- a magnetic component may be incorporated into one or more individual components of the dual-stage syringes so that the magnetic components such individual components may produce one or more magnetic fields.
- the primary plunger may include one or more magnetic components.
- the primary plunger 50 may have a secondary chamber defined through the primary plunger 50 from a proximal opening of the primary plunger 50 to a sealed distal end of the primary plunger 50 .
- the primary plunger 50 may include one or more magnetic components in the plunger body portion 55 so that the magnetic components included in the plunger body portion 55 may produce a magnetic field.
- the one or more magnetic components may produce a magnetic field that repels a diamagnetic material of a plurality of microspheres.
- This repulsion between the one or more magnetic components and the diamagnetic material of the plurality of microspheres may cause the plurality of microspheres to levitate within embodiments of the dual-stage syringe.
- the magnetic components incorporated into embodiments of the dual-stage syringes described herein may reduce interaction or binding of radiotherapeutic microspheres with the dual-stage syringes, which may prevent browning and/or embrittlement of the materials used to form embodiments of the dual-stage syringes described herein.
- the magnetic components incorporated into components of the dual-stage syringes described herein may produce non-uniform magnetic fields, for example, along the plunger body portion 55 of the primary plunger 50 , which may facilitate the mixing of radiotherapeutic microspheres in a suspension medium such as saline.
- the dual-stage syringes may include any suitable gamma compatible material.
- a gamma compatible material may be any radiation-stable, medical-grade polymer material. The radiation stability of the gamma compatible material may be dependent on the tolerance level of the particular type of medical grade polymer material. Once the container material absorbs a radiation dose that exceeds the container material's tolerance level, browning or embrittlement of the dual-stage syringe may occur.
- Exemplary gamma compatible materials include, but are not limited to, thermoplastics, including acrylonitrile/butadiene/styrene, aromatic polyesters, cellulosics, fluoropolymers, polyacetals, polyacrylics, polyamides, polyethylenes polyimides, polymethylpentene, polyphenylene sulfide, polypropylenes, polystyrenes, polysulfones, polyurethanes, polyvinylbutyral, polyvinylchloride, polyvinylidene chloride, styrene/acrylonitrile; thermosets including allyl digylcol carbonate, epoxies, phenolics, polyesters, polyurethanes, and elastomers including butyl, ethylene-propylene diene monomer, fluoro elastomers, natural rubbers, nitriles, polyacrylics, polychloroprenes, silicones, styrene
- the dual-stage syringe may be made from a gamma compatible material with a tolerance level of from about 5 kGy to about 100,000 kGy, from about 5 kGy to about 10,000 kGy, from about 5 kGy to about 5,000 kGy, from about 5 kGy to about 1,000 kGy, from about 5 kGy to about 500 kGy, from about 5 kGy to about 100 kGy, from about 100 kGy to about 100,000 kGy, from about 100 kGy to about 10,000 kGy, from about 100 kGy to about 5,000 kGy, from about 100 kGy to about 1,000 kGy, from about 100 kGy to about 500 kGy, from about 500 kGy to about 100,000 kGy, from about 500 kGy to about 10,000 kGy, from about 500 kGy to about 10,000 kGy, from about 500 kGy to about 10,000 kGy,
- the dual-stage syringe may include one or more magnetic fields.
- the one or more magnetic fields of the dual-stage syringe may interact with the plurality of microspheres in a manner that prevents direct contact of the plurality of microspheres to the dual-stage syringe.
- the one or more magnetic fields of the dual-stage syringe may interact with the plurality of microspheres in a manner that facilitates mixing of the plurality of microbeads. The mixing may, at least in part, be facilitated by the shape of the dual-stage syringe.
- the strength, location, and pattern of the one or more magnetic fields of the dual-stage syringe may vary.
- the magnetic fields may be of sufficient magnitude to levitate or repel the plurality of microspheres off the surface of the dual-stage syringe. This magnitude may be depend on various factors, including the radiation tolerance of the materials included in the dual-stage syringe; the amount of therapeutic agent in the microsphere, more specifically, the amount of radiotherapeutic material in the microsphere; the type of therapeutic agent in the microsphere, more specifically, the amount of radiotherapeutic material in the microsphere; the amount (mass) of microsphere material, the type of microsphere material, the amount (mass) of diamagnetic material in the microsphere, the type of diamagnetic material in the microsphere, and combinations of these factors.
- the magnetic fields may be of sufficient magnitude to levitate or repel the plurality of microspheres at a height sufficient to prevent browning or embrittlement of the dual-stage syringe.
- multiple magnetic fields may be present within the dual-stage syringe as a result of magnetic components incorporated within features of the dual-stage syringe.
- the multiple magnetic fields may have varying strengths. For example, at least a portion of the magnetic fields of the dual-stage syringe may be of a lesser strength, and at least a portion of the magnetic fields of the dual-stage syringe may be of a greater strength.
- the varying strengths of the magnetic fields of the dual-stage syringe may facilitate mixing of the plurality of microspheres within the dual-stage syringe.
- the magnetic fields of the dual-stage syringe may be produced by incorporating one or more magnetic components into the walls of the dual-stage syringe's individual components. In other embodiments, the magnetic fields of the dual-stage syringe may be produced by surrounding the dual-stage syringe with one or more magnetic components.
- the walls of the containers described herein comprise one or more magnetic components
- the walls may comprise any number of individual magnetic components (e.g., one, two, three, four, five, six, seven, or eight or more, etc.). Each magnetic component may be fixed in or on the dual-stage syringe by any suitable method.
- one or more magnetic components may be embedded in, adhered to, or friction-fit within the dual-stage syringe by any suitable manufacturing methods, including by painting, over-molding, printing, or gluing the one or more magnetic components onto the dual-stage syringe.
- each magnetic component may not be fixed in or on the dual-stage syringe, so the magnetic fields produced by the magnetic components may be mobile.
- each magnetic component may be embedded in, adhered to, or friction-fit within a casing, cover, or other external component that surrounds at least a portion of the dual-stage syringe.
- the magnetic component may include a permanent magnet.
- the magnet may be made of any suitable material capable of generating a magnetic field.
- the magnetic components may be permanent magnets made out of ferromagnetic materials.
- the magnetic components may comprise one or more rare-earth magnets, cobalt, gadolinium, iron, nickel, alloys of these metals with or without other metals such as alnico, chemical compounds such as ferrites, or a combination of any of these metals or their alloys.
- the rare-earth magnets may include samarium cobalt magnets or neodymium magnets.
- the magnetic component may include an electromagnet.
- the electromagnet may be selectively activated to produce a magnetic field.
- the electromagnets may be activated before the plurality of microspheres are loaded in the dual-stage syringe; the electromagnets may remain activated during storage of the plurality of microspheres to levitate the plurality of microspheres and keep them from settling in the dual-stage syringe; and then the electromagnets may be deactivated after the plurality of microspheres are removed from the dual-stage syringe or after the radioembolization procedure is complete.
- the dual-stage syringe comprises multiple electromagnets
- these magnetic components may be independently activated or may be activated as a group.
- the one or more electromagnets may be selectively activated by an electronic interaction, such as by a battery and a switch or other suitable activating means.
- the one or more electromagnets may be selectively activated in a manner to create one or more pulsating magnetic fields.
- multiple electromagnets may be selectively activated in a manner to create multiple pulsating magnetic fields with varying magnitudes.
- the dual-stage syringe may include multiple magnetic components.
- the multiple magnetic components may be any combination of permanent magnets, ferromagnetic components, or electromagnets.
- only side walls of the dual-stage syringe may include permanent magnets.
- base wall may include only permanent magnets, only ferromagnetic components, only electromagnets, or a mix of some or all of these elements.
- the side walls of the dual-stage syringe may include permanent magnets, and the base wall or a lid may include only electromagnets that may be activated after the plurality of microspheres have been loaded into the dual-stage syringe.
- each magnetic component may have any suitable size and shape.
- each magnetic component may be cylindrical, semi-cylindrical, tube-shaped, box-shaped, planar, spherical, or the like.
- the dimensions of the magnetic components may be constrained by size of the dual-stage syringes carrying the magnetic components, which in turn may be constrained by the radioembolization procedure itself.
- the radioembolization procedure may require a specific dose or delivery device, in which case, the dual-stage syringe may be specifically sized to accommodate said dose or fit within said delivery device.
- Each magnetic component may have any suitable length. In some embodiments, each magnetic component may have a length of about 5 mm, about 10 mm, about 15 mm, about 20 mm, or each magnetic component may extend along the entire length of one wall of the dual-stage syringe.
- FIG. 41 is a schematic of an exemplary delivery system 2000 into which the sleeved locking dual-stage syringe 200 may be incorporated.
- Further exemplary delivery systems include those disclosed in U.S. App. No. [Attorney Docket No. P-18891], entitled “RADIOEMBOLIZATION DELIVERY DEVICE,” filed concurrently with the present disclosure, which application is incorporated herein by reference in its entirety.
- the sleeved locking dual-stage syringe 200 and additional components may be housed within a system housing, as schematically illustrated in FIG. 40 by dotted lines surrounding the components of the exemplary delivery system 2000 .
- the sleeved locking dual-stage syringe 200 may include geometry (orientation) features that adapt the sleeved locking dual-stage syringe 200 to be received in the exemplary delivery system 2000 .
- geometry features may include features that orient the sleeved locking dual-stage syringe 200 in the exemplary delivery system 2000 or features that lock the sleeved locking dual-stage syringe 200 in place within the exemplary delivery system 2000 .
- the sleeved locking dual-stage syringe 200 is illustrated in the punctured configuration, at which a delivery needle 150 held in place by a needle mount 2100 provides fluidic communication between a system reservoir 2200 and the secondary chamber 95 of the sleeved locking dual-stage syringe 200 .
- One or more additional fluidic reservoirs 2300 may be included in the exemplary delivery system 2000 for adding additional fluids to the delivery mixture formed in the sleeved locking dual-stage syringe 200 as previously described.
- the system reservoir 2200 and the additional fluidic reservoirs 2300 may be fluidically coupled to a mixing valve 2500 through coupling lines 2250 , 2400 .
- the mixing valve may be fluidically coupled to a delivery valve 2700 through an exit line 2600 .
- the delivery valve 2700 may be fluidically coupled to a delivery device 2800 such as a catheter or a microcatheter, for example, which is intravenously fluidically coupled to the patient being treated.
- horizontal and vertical are relative terms only, are indicative of a general relative orientation only, and do not necessarily indicate perpendicularity. These terms also may be used for convenience to refer to orientations used in the figures, which orientations are used as a matter of convention only and are not intended as characteristic of the devices shown. The present disclosure and the embodiments thereof to be described herein may be used in any desired orientation. Moreover, horizontal and vertical walls need generally only be intersecting walls, and need not be perpendicular.
- the term “substantially” is used herein to represent the inherent degree of uncertainty that may be attributed to any quantitative comparison, value, measurement, or other representation.
- the term “substantially” is used herein also to represent the degree by which a quantitative representation may vary from a stated reference without resulting in a change in the basic function of the subject matter at issue. As such, it is used to represent the inherent degree of uncertainty that may be attributed to any quantitative comparison, value, measurement, or other representation, referring to an arrangement of elements or features that, while in theory would be expected to exhibit exact correspondence or behavior, may in practice embody something slightly less than exact.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Primary Health Care (AREA)
- Medical Informatics (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
- This application claims the benefit of priority to U.S. Provisional App. No. 62/673,632, entitled “RADIOEMBOLIZATION DELIVERY DEVICE” filed May 18, 2018, the disclosure of which is incorporated by reference herein; and to U.S. Provisional App. No. 62/673,628, entitled “DUAL-STAGE SYRINGES WITH LOCKING MECHANISM” filed May 18, 2018, the disclosure of which is incorporated by reference herein.
- The present disclosure relates generally to syringes and, more particularly, to dual-stage syringes that deliver multiple fluids independently.
- In cancer treatments involving radiation therapy, inadvertent or excess exposure to radiation from radioactive therapeutic agents can be harmful and potentially lethal to patients or medical personnel. Accordingly, medical instruments for radiation therapies must be configured to localize the delivery of radioactive material to a particular area of the patient's body while shielding others from unnecessarily being exposed to radiation.
- Transarterial Radioembolization is a transcatheter intra-arterial procedure performed by interventional radiology and is commonly employed for the treatment of malignant tumors. During this medical procedure, a microcatheter is navigated into a patient's liver, where radioembolizing microspheres loaded with a radioactive compound, such as yttrium-90 (90Y or Y90), are delivered to the targeted tumors. The microspheres embolize blood vessels that supply the tumors while also delivering radiation to kill tumor cells.
- Generally, medical devices for performing radioembolization procedures require multiple syringes, external tubing, a vial containing the radioactive compound, and a bulky shield assembly for containing and shielding the radioactive vial. Such devices typically involve time consuming and labor-intensive setup procedures. The complex devices are commonly stationary and thereby limit a physician's mobility in an operating room to within a certain proximity of the device.
- Routine manipulation of a product container storing radioactive material during radioembolization procedures generally requires a Nuclear Medicine Technician, who handles the material with forceps or tweezers. This process involves further potential of exposing additional medical personnel to radioactivity, and contaminating the operating room. Syringes for manually administering the radioactive compound are prone to inconsistent flow rates and pressures. Insufficient injection rates result in decreased bead dispersion, which may impact efficacy of the treatment.
- Embodiments of the present disclosure are to be used in any technical setting where it is necessary to deliver two separate and isolated media, such as during Transarterial Radioembolization for the treatment of malignant liver tumors. During a Transarterial Radioembolization procedure, a microcatheter is navigated into the liver, and a therapeutic agent, such as a radiotherapeutic agent included in microspheres, may be delivered to the targeted tumors. Throughout this procedure, different media may be used including saline/D5W, contrast agent, and the microspheres. As a result, a minimum of three different syringes are necessary, resulting in increased setup and operating time. Another issue make arise during Transarterial Radioembolization procedures when using a traditional style syringe, as two or more separate syringes are needed during the device activation. The first syringe may be an empty or prefilled syringe of saline for pumping. During the exchange of two or more independent syringes, there is a risk of air entering the system.
- This disclosure describes a dual-stage syringe having two independent reservoirs that are engaged in series via a single plunger for the injection or distribution of two separate media. In embodiments, the dual-stage syringes disclosed herein may be manually driven.
- The dual-stage syringes of the present disclosure may include a single plunger mechanism, which is used to actuate both chambers, and the medium in each chamber is delivered independently. The dual-stage syringes of the present disclosure may allow for the internal or proximal chamber to be filled and purged multiple times without actuating the external or distal chamber. Additionally, some embodiments of the dual-stage syringes disclosed herein may include one or more locking mechanisms, which may provide tactile and audible feedback and assurance for when the various media are exchanged.
- Embodiments of the present disclosure may also address one or more of the following shortcomings of existing systems: Difficulty in pushing syringes to pressurize liquids to flow through the microcatheter, numerous cumbersome steps that delay the procedure and cause unnecessary radiation exposure (e.g. turing stopcocks, adjusting needle heights, adjusting tubing sets to dislodge trapped spheres, etc.), inability to control bead flow, delivery volume and delivery rate, inability to easily assay the contained Y90 activity as part of quality-assurance steps, inability to split the therapeutic dose easily to allow treatment at different tumor sites, settling of particles or microspheres in containers or tubings due to inability to mix the particles or microspheres spheres and a cumbersome overall size of devices used for Transarterial Radioembolization, which take up valuable room and access in the operating room.
- Example embodiments disclosed herein are directed to locking-mechanism dual-stage syringes.
- These and other features, aspects, and advantages of the present disclosure will become better understood with reference to the following description and the appended claims.
- Additional features and advantages of the embodiments described herein will be set forth in the detailed description which follows, and in part will be readily apparent to those skilled in the art from that description or recognized by practicing the embodiments described herein, including the detailed description which follows, the claims, as well as the appended drawings.
- It is to be understood that both the foregoing general description and the following detailed description describe various embodiments and are intended to provide an overview or framework for understanding the nature and character of the claimed subject matter. The accompanying drawings are included to provide a further understanding of the various embodiments, and are incorporated into and constitute a part of this specification. The drawings illustrate the various embodiments described herein, and together with the description serve to explain the principles and operations of the claimed subject matter.
-
FIG. 1 is a schematic of a dual-stage syringe according to embodiments. -
FIG. 2 is a side view of an external barrel of a dual-stage syringe according to embodiments. -
FIG. 3 is a top perspective view of an external barrel of a dual-stage syringe according to embodiments. -
FIG. 4 is a bottom perspective view of an external barrel of a dual-stage syringe according to embodiments. -
FIG. 5 is a side perspective view of an external barrel of the dual-stage syringe according to embodiments. -
FIG. 6 is a side view of a primary plunger of a dual-stage syringe according to embodiments. -
FIG. 7 is a top perspective view of a primary plunger of a dual-stage syringe according to embodiments. -
FIG. 8 is a side perspective view of a primary plunger of a dual-stage syringe according to embodiments. -
FIG. 9 is a side perspective view of a primary plunger of a dual-stage syringe, including a sealing member on the distal end thereof, according to embodiments. -
FIG. 10 is a side perspective view of a primary plunger of a dual-stage syringe, including a sealing member on the distal end thereof, according to embodiments. -
FIG. 11 is an exploded view of a sleeved dual-stage syringe according to embodiments. -
FIG. 12 is a side perspective view of a locking sleeve, according to embodiments. -
FIG. 13 is a bottom perspective view of the locking sleeve, according to embodiments. -
FIG. 14 is a bottom view of the locking mechanism of the locking sleeve, according to embodiments. -
FIG. 15 is a top perspective view of the locking sleeve, according to embodiments. -
FIG. 16 is a side perspective view of an assembly including the locking mechanism and the primary plunger having a sealing member on the distal end thereof, according to embodiments. -
FIG. 17 is a front view of an assembly including the locking mechanism and the primary plunger having a sealing member on the distal end thereof, according to embodiments. -
FIG. 18 is a side view of a secondary plunger of a dual-stage syringe, according to embodiments. -
FIG. 19 is a perspective view of a sleeved locking dual-stage syringe according to embodiments, in a shipment configuration. -
FIG. 20 is a perspective view of the sleeved locking dual-stage syringe ofFIG. 16 , in a shipment configuration with primary plunger and locking mechanism visible through the external barrel. -
FIG. 21 is a longitudinal cross-section of the sleeved locking dual-stage syringe ofFIGS. 19 and 20 in a shipment configuration. -
FIG. 22 is a perspective view of a sleeved locking dual-stage syringe according to embodiments, in a flushed configuration with primary plunger and locking mechanism visible through the external barrel. -
FIG. 23 is a longitudinal cross-section of the sleeved locking dual-stage syringe ofFIG. 22 in a flushed configuration. -
FIG. 24 is a perspective view of a sleeved locking dual-stage syringe according to embodiments, in a punctured configuration with primary plunger and locking mechanism visible through the external barrel. -
FIG. 25 is a longitudinal cross-section of the sleeved locking dual-stage syringe ofFIG. 23 in a punctured configuration. -
FIG. 26 is a cut-away view of a sleeved locking dual-stage syringe according to embodiments, in a primed configuration with primary plunger and locking mechanism visible through the external barrel. -
FIG. 27 is a longitudinal cross-section of the sleeved locking dual-stage syringe ofFIG. 26 in a primed configuration. -
FIG. 28 is a perspective view of a sleeved locking dual-stage syringe according to embodiments, in a delivery configuration. -
FIG. 29 is a longitudinal cross-section of the sleeved locking dual-stage syringe ofFIG. 28 in a delivery configuration. -
FIG. 30 is a side perspective view of a turn-key locking dual-stage syringe according to embodiments. -
FIG. 31 is a side perspective view of the secondary plunger and sealing member of the turn-key locking dual-stage syringe ofFIG. 30 . -
FIG. 32 is a side perspective view of an assembly of the primary plunger, the secondary plunger, and the sealing member of the turn-key locking dual-stage syringe ofFIG. 30 . -
FIG. 33 is a side cross section view of an integrated one-way valve syringe, according to embodiments. -
FIG. 34A is a side cross section view of the integrated one-way valve syringe ofFIG. 33 in a first stage, according to embodiments. -
FIG. 34B is a side cross section view of the integrated one-way valve syringe ofFIG. 33 in a second stage, according to embodiments. -
FIG. 34C is a side cross section view of the integrated one-way valve syringe ofFIG. 33 in a third stage, according to embodiments. -
FIG. 35 is a side cross section view of an integrated one-way valve syringe according to embodiments. -
FIG. 36A is a side cross section view of the integrated one-way valve syringe ofFIG. 35 in a first stage, according to embodiments. -
FIG. 36B is a side cross section view of the integrated one-way valve syringe ofFIG. 35 in a second stage, according to embodiments. -
FIG. 36C is a side cross section view of the integrated one-way valve syringe ofFIG. 35 in a third stage, according to embodiments. -
FIG. 37 is a schematic of a sleeved locking dual-stage syringe with membrane technology according to embodiments. -
FIG. 38 is a side view of a syringe with a ratcheting safety tab, according to embodiments. -
FIG. 39 is a side cross-section view of a syringe with a ratcheting safety tab, according to embodiments. -
FIG. 40A is top view of a telemeterized syringe plunger cap, according to embodiments. -
FIG. 40B is section view of a telemeterized syringe plunger cap, according to embodiments. -
FIG. 40C is a section view of a telemeterized syringe plunger cap assembled on a syringe plunger, according to embodiments. -
FIG. 41 is a schematic of a sleeved locking dual-stage syringe according to embodiments, incorporated into an example of a radioembolization delivery system for delivery of radioembolization bead solutions to a patient through a delivery catheter in fluidic communication with the sleeved locking dual-stage syringe. - Reference will now be made in detail to embodiments of dual-stage syringes. In particular, embodiments of the dual-stage syringes disclosed herein may be directed to locking-mechanism dual-stage syringes and dual-stage syringes having integrated one-way valves. As will be subsequently described in more detail, embodiments of locking-mechanism dual-stage syringes may include sleeved dual-stage syringes. As will be subsequently described in more detail, other embodiments of locking-mechanism dual-stage syringes may include turn-key dual-stage syringes. In other embodiments of the dual-stage syringes described herein, dual-stage syringes having one or more integrated one-way valves will be subsequently described in more detail.
- The dual-stage syringes may be incorporated into any system involving delivering or mixing multiple fluids including medical procedures involving delivery of multiple fluids such as therapeutic agents, flushing solutions, excipient solutions, isotonic sterile solutions, contrast agents, or combinations thereof. In some embodiments, the dual-stage syringes may be incorporated into delivery systems for cancer treatments such as, for example, in delivery systems for chemotherapeutic agents or radiotherapeutic agents. In some embodiments, the dual-stage syringes may be incorporated into delivery systems for chemoembolization therapy or radioembolization therapy, such as for fluids containing radioembolization beads that are mixed with one or more carrier solutions or contrast agents in preparation for being delivered to a patient in need of the therapy. In some embodiments, the dual-stage syringes may be incorporated into delivery systems for transarterial radioembolization for tumor treatments such as, for example, liver-tumor treatments.
- As used herein with regard to embodiments of the dual-stage syringes, the relative term “distal” means in the direction toward which a plunger is inserted into a barrel of the dual-stage syringes and in which a fluid is expelled from the dual-stage syringe during operation of the dual-stage syringe. Likewise, the relative term “proximal” means opposite the direction toward which the plunger is inserted into a barrel of the dual-stage syringes and in which the fluid is expelled from the dual-stage syringe during operation of the dual-stage syringe. It should be understood, in general, that directional terms as used herein—for example up, down, right, left, front, back, top, bottom, distal, and proximal—are made only with reference to the figures as drawn and are not intended to imply absolute orientation of any device, of any device component, or of any embodiment as a whole.
- Reference will now be made in detail to embodiments of locking-mechanism dual-stage syringes. In embodiments, the locking-mechanism dual-stage syringes may include an external barrel, a primary plunger, and one or more locking mechanisms.
- The one or more locking mechanisms may be configured to define a first boundary, a second boundary, and at least three stages. The second boundary may be distal to the first boundary. The at least three stages may include an initial stage, an intermediate stage, and a final stage. In the initial stage, the primary plunger is inserted proximal to the first boundary and may be freely movable distally or proximally. In the intermediate stage, the primary plunger is inserted distal to the first boundary and is prevented from moving proximally beyond the first boundary. In the final stage, the primary plunger is inserted distal to the second boundary and is prevented from moving proximally beyond the second boundary.
- In some embodiments, the one or more locking mechanisms may be incorporated into the external barrel, the primary plunger, one or more additional components, or combinations thereof. In further embodiments, the one or more locking mechanisms may be incorporated as a feature on the surface of the external barrel, primary plunger, one or more additional components, or combinations thereof. Such features may be a male feature including one or more nibs, projections, protrusions, or combinations thereof. In embodiments, such features may be a female feature including one or more grooves, tracks, indentations, depressions, other surface modifications, or combinations thereof. In some embodiments, a male feature may have a corresponding female feature. In some embodiments, the one or more locking mechanisms may include a sleeved locking mechanism, a turn-key locking mechanism, or other locking mechanisms.
- Referring to
FIG. 1 , a locking-mechanism dual-stage syringe 100 is provided according to embodiments. In the embodiment exemplified inFIG. 1 , the locking-mechanism dual-stage syringe 100 may include anexternal barrel 10, a primary plunger (piston) 50, that accommodates asecondary plunger 70. In the exploded view ofFIG. 1 , locking-mechanism dual-stage syringe 100 are depicted as aligned along a longitudinal axis 1 shared by theindividual components stage syringe 100 itself, when fully assembled. In embodiments of the locking-mechanism dual-stage syringe 100 fully assembled, particular configurations of which will be described subsequently in greater detail, at least a portion of theprimary plunger 50 is accommodated within theexternal barrel 10, and at least a portion of the secondary plunger may be accommodated within theprimary plunger 50. Each of the foregoingindividual components stage syringe 100, will now be described in greater detail. - The locking-mechanism dual-
stage syringe 100 may include anexternal barrel 10. Referring now toFIGS. 1-5 , theexternal barrel 10 may have aprimary chamber 90 defined through theexternal barrel 10 from a proximal opening of theexternal barrel 10 to a distal opening of theexternal barrel 10. - In embodiments, the
external barrel 10 may be made of various materials such as, for example, polymers, plastics, or metals. Non-limiting example polymers for the external barrel include polycarbonates (PC), polyethylenes (PE), polyethylene terephthalates (PET). Non-limiting example plastics for theexternal barrel 10 include poly(methyl methacrylate) (PMMA) and composite resins such as polycarbonate loaded with tungsten. Non-limiting example metals and metal alloys for theexternal barrel 10 include stainless steel, titanium, copper, tungsten, aluminum, pewter, and various alloys of any of these. In some embodiments, theexternal barrel 10 is made of a radiation shielding material such as the plastics or metals previously listed. The radiation shielding material may have a thickness sufficient to ensure that radiation from a radioactive therapeutic material in the dual-stage syringe having a one ormore locking mechanisms 100 cannot penetrate to the environment or cause safety concerns for personnel operating the locking-mechanism dual-stage syringe 100. In embodiments, suitable radiation shielding materials may shield operators of the dual-stage syringe having asleeved locking mechanism 100 from beta-particle radiation, from x-rays, or both. - Referring now to
FIGS. 2-4 , an exemplary embodiment of theexternal barrel 10 is provided. In all exemplary embodiments provided inFIGS. 2-4 , theexternal barrel 10 of the locking-mechanism dual-stage syringe 100 may include an externalproximal opening 11, a proximal flarededge 13 around the externalproximal opening 11, an externaldistal opening 19 opposite the externalproximal opening 11, and abody portion 15 between the proximal flarededge 13 and the externaldistal opening 19. Referring toFIG. 2 , theexternal barrel 10 may include aneck portion 17 between thebody portion 15 and the externaldistal opening 19. - Referring to
FIG. 3 , theexternal barrel 10 may optionally include aproximal depression 12 that may be configured to accommodate corresponding features of theprimary plunger 50, as described subsequently in greater detail. The externalproximal opening 11 of theexternal barrel 10 may be sufficiently wide to accommodate theprimary plunger 50 through the externalproximal opening 11. As will be described subsequently in more detail, in embodiments, the externalproximal opening 11 of theexternal barrel 10 may be sufficiently wide to accommodate a locking mechanism, such as a sleeved locking mechanism, through the externalproximal opening 11. Referring still toFIG. 3 , theexternal barrel 10 has aprimary chamber 90 defined therein. Theprimary plunger 50 may be insertable intoprimary chamber 90. In some embodiments, a locking mechanism may be insertable intoprimary chamber 90. - Referring to
FIG. 4 , theexternal barrel 10 optionally may include gripping features 14 on a distal-facing side of the proximal flarededge 13. - As stated previously, in some embodiments of the locking-mechanism dual-
stage syringe 100, the one or more locking mechanisms may be incorporated into theexternal barrel 10. In such embodiments, the one or more locking mechanisms incorporated into theexternal barrel 10 as one or more features on the surface of theexternal barrel 10, such as male features and/or female features. Male features may include, without limitation, nibs, projections, protrusions, or combinations thereof. Female features may include, without limitation, grooves, tracks, indentations, depressions, other surface modifications, and combinations thereof. - In embodiments, the
external barrel 10 may include one or more male features on the surface of theexternal barrel 10. In further embodiments, the one or more male features on the surface of theexternal barrel 10 may have corresponding one or more female features on theprimary plunger 50, one or more additional components, or combinations thereof. In other embodiments, theexternal barrel 10 may include one or more female features on the surface of theexternal barrel 10. In further embodiments, the one or more female features on the surface of theexternal barrel 10 may have a corresponding one or more male features on the primary plunger, one or more additional components, or combinations thereof. In some embodiments, theexternal barrel 10 may include a combination of male and female features on the surface of theexternal barrel 10, which may have corresponding female and male features, respectively, on the primary plunger, one or more additional components, or combinations thereof. -
FIG. 5 shows an exemplary embodiment a locking-mechanism dual-stage syringe 100 having one or more locking mechanisms incorporated into theexternal barrel 410. Referring now toFIG. 5 , embodiments of anexternal barrel 410 may include an initial-stage track 412, an intermediate-stage track 414, and a final-stage track 416 within theexternal barrel 410. The initial-stage track 412, the intermediate-stage track 414, and the final-stage track 416 are all female features on the surface ofexternal barrel 410. InFIG. 5 ,indentations 418 are also female features on the surface ofexternal barrel 410. Collectively, the initial-stage track 412, the intermediate-stage track 414, the final-stage track 416, and theindentations 418 may be referred to as the female features of the locking mechanism of the embodiment illustrated inFIG. 5 . As will be described subsequently in more detail, the female features of the locking mechanism of the embodiment illustrated inFIG. 5 have corresponding male features on the primary plunger of the embodiment illustrated inFIG. 5 . Collectively, the male features and female features of the locking mechanism of the embodiment illustrated inFIG. 5 may be collectively referred to as the turn-key locking mechanism of the embodiment illustrated inFIG. 5 . As such, the embodiment illustrated inFIG. 5 may also be referred to as a turn-key embodiment of the locking-mechanism dual-stage syringe 100. In other embodiments, the locking-mechanism dual-stage syringe 100 may include a turn-key locking mechanism that includes only the initial-stage track 412, the intermediate-stage track 414, and the final-stage track 416 but not theindentations 418. In yet other embodiments, the locking-mechanism dual-stage syringe 100 may include a turn-key locking mechanism that includes the initial-stage track 412, the intermediate-stage track 414, the final-stage track 416, theindentations 418, and one or more additional locking mechanisms. - Referring still to
FIG. 5 , the intersection of the initial-stage track 412 with the intermediate-stage track 414 corresponds to an initial stage of the primary plunger. In the initial stage, the primary plunger is inserted proximal to the initial-stage track 412 and may be freely movable distally or proximally. The intermediate-stage track 414 corresponds to an intermediate stage of the primary plunger. In the intermediate stage, the primary plunger may traverse the intermediate-stage track and is prevented from moving proximally beyond the intermediate-stage track. The intersection of the final-stage track 416 with the intermediate-stage track 414 corresponds to a final stage of the primary plunger. In the final stage, the primary plunger is inserted distal to the intermediate-stage track and is prevented from moving proximally beyond a distal end of the final-stage track. In other embodiments, the locking-mechanism dual-stage syringe 100 may include a turn-key locking mechanism that includes one or more additional tracks in the surface of theexternal barrel 410, which may define one or more additional stages. - Like other embodiments of the
external barrel 10, theexternal barrel 410 may include any of the polymers, plastics, metals, or alloys listed previously, or it may include other materials, such as nylon. - Reference will now be made to embodiments of the
primary plunger 50 of the locking-mechanism dual-stage syringe 100. Referring back toFIG. 1 , theprimary plunger 50 may have a secondary chamber defined through theprimary plunger 50 from a proximal opening of theprimary plunger 50 to a sealed distal end of theprimary plunger 50, theprimary plunger 50 configured to receive a secondary plunger (piston) 70 through the proximal opening of theprimary plunger 50. In embodiments, theprimary plunger 50 may be sufficiently narrow to be accommodated byexternal barrel 10. - In embodiments, the
primary plunger 50 may be made of various materials such as, for example, polymers, plastics, or metals. Non-limiting example polymers for the external barrel include polycarbonates (PC), polyethylenes (PE), polyethylene terephthalates (PET). Non-limiting example plastics for theprimary plunger 50 include poly(methyl methacrylate) (PMMA) and composite resins such as polycarbonate loaded with tungsten. Non-limiting example metals and metal alloys for theprimary plunger 50 include stainless steel, lead, copper, tungsten, aluminum, pewter, and various alloys of any of these. In some embodiments, theprimary plunger 50 is made of a radiation shielding material such as the plastics or metals previously listed. The radiation shielding material may have a thickness sufficient to ensure that radiation from a radioactive therapeutic material in the dual-stage syringe having a one ormore locking mechanisms 100 cannot penetrate to the environment or cause safety concerns for personnel operating the locking-mechanism dual-stage syringe 100. In embodiments, suitable radiation shielding materials may shield operators of the dual-stage syringe having asleeved locking mechanism 100 from beta-particle radiation, from x-rays, or both. - Referring now to
FIGS. 6-9 , an exemplary embodiment of theprimary plunger 50 is provided. InFIGS. 6-9 , theprimary plunger 50 may include aproximal wing portion 51, adistal plunger opening 53, and aplunger body portion 55. The primary plunger may include asecondary chamber 95 defined therein from theproximal wing portion 51 to thedistal plunger opening 53. Theprimary plunger 50 optionally may include handle-locking features 52 on theproximal wing portion 51. Thesecondary chamber 95 may accommodate thesecondary plunger 70, which will be described subsequently in more detail. Theplunger body portion 55 may include one or more stop rings such as adistal stop ring 56 and aproximal stop ring 58. In some embodiments, both thedistal stop ring 56 and theproximal stop ring 58 may be configured to interact with embodiments of a locking mechanism, subsequently described in more detail, as theprimary plunger 50 is moved. - Referring now to
FIGS. 8-9 , in embodiments, theprimary plunger 50 may include aseal seat 59 for mounting a plunger seal 60. The plunger seal 60 may include one-way valves, flaps, or flow channels. As shown inFIG. 9 , in embodiments, the plunger seal 60 may be mounted on the primary plunger, such that the plunger seal 60 covers thedistal plunger opening 53 to prevent fluidic flow through thedistal plunger opening 53 until an appropriate stage in the operation of the locking-mechanism dual-stage syringe 100, as will be described in greater detail. - In some embodiments of the locking-mechanism dual-
stage syringe 100, one or more locking mechanisms may be incorporated into the primary plunger. In such embodiments, the one or more locking mechanisms incorporated into the primary plunger may include one or more features on the surface of the primary plunger, such as male features and/or female features. Male features may include, without limitation, nibs, projections, protrusions, or combinations thereof. Female features may include, without limitation, grooves, tracks, indentations, depressions, other surface modifications, and combinations thereof. - In embodiments, the
primary plunger 50 may include one or more male features on the surface of theprimary plunger 50. In further embodiments, the one or more male features on the surface of theprimary plunger 50 may have corresponding one or more female features on the external barrel, one or more additional components, or combinations thereof. In other embodiments, theprimary plunger 50 may include one or more female features on the surface of theprimary plunger 50. In further embodiments, the one or more female features on the surface of theprimary plunger 50 may have a corresponding one or more male features on the external barrel, one or more additional components, or combinations thereof. In some embodiments, theprimary plunger 50 may include a combination of male and female features on the surface of theprimary plunger 50, which may have corresponding female and male features, respectively, on the external barrel, one or more additional components, or combinations thereof. -
FIG. 10 shows an exemplary embodiment of a locking-mechanism dual-stage syringe incorporated into the primary plunger. Referring now toFIG. 10 , embodiments of aprimary plunger 450 includes male features (nibs) 465, which are shaped and sized appropriately to correspond the female features of the turn-key locking mechanism ofFIG. 5 , previously described. In embodiments male features the may be shaped and sized appropriately to travel within thetracks external barrel 410. - As previously stated, the one or more locking mechanisms of the locking-mechanism dual-
stage syringe 100 may be configured to define a first boundary, a second boundary, and at least three stages. The second boundary may be distal to the first boundary. The at least three stages may include an initial stage, an intermediate stage, and a final stage. In the initial stage, the primary plunger is inserted proximal to the first boundary and may be freely movable distally or proximally. In the intermediate stage, the primary plunger is inserted distal to the first boundary and is prevented from moving proximally beyond the first boundary. In the final stage, the primary plunger is inserted distal to the second boundary and is prevented from moving proximally beyond the second boundary. - In some embodiments, the one or more locking mechanisms may be incorporated into a sleeve disposed within the
primary chamber 90. For example, the one or more locking mechanisms incorporated into a sleeve disposed within theprimary chamber 90 may include a feature on the surface of the sleeve disposed within theprimary chamber 90 such as a nib, projection, protrusion, groove, track, indentation, or other surface modification. An example of a locking mechanism incorporated into a sleeve disposed within theprimary chamber 90 may include a sleeved locking mechanism, which will now be described in greater detail. - Embodiments of dual-stage syringes having sleeved locking mechanisms will now be described with reference to
FIGS. 11-15 . Referring toFIG. 11 , a dual-stage syringe having asleeved locking mechanism 200 according to embodiments may include anexternal barrel 210, a lockingsleeve 230, and aprimary plunger 250 that accommodates asecondary plunger 270. In the exploded view ofFIG. 11 , the components of the dual-stage syringe having a sleeved locking mechanism 300 are depicted as aligned along alongitudinal axis 31 shared by theindividual components sleeved locking mechanism 200 itself, when fully assembled. In a dual-stage syringe having asleeved locking mechanism 200 fully assembled, particular configurations of which will be described subsequently in greater detail, the lockingsleeve 230 is accommodated within theexternal barrel 210, at least a portion of theprimary plunger 250 is accommodated within the lockingsleeve 230 and theexternal barrel 210, and at least a portion of thesecondary plunger 270 may be accommodated within theprimary plunger 250. - Referring again to
FIGS. 11-15 , embodiments of the dual-stage syringe having asleeved locking mechanism 200 may include a lockingsleeve 230. Referring toFIGS. 11-15 , thelocking mechanism 230 according to embodiments may include abody portion 235 having a shape conforming to contours of theexternal barrel 10. Thelocking mechanism 230 may include one or more features that can be used for integrational assembly, such as aproximal ridge 232 configured to seat the locking mechanism in the externalproximal opening 11 of theexternal barrel 10. Thelocking mechanism 230 may includedistal catch members 240. Thedistal catch members 240 may have various shapes and dimensions suited to perform a locking function, as will be described subsequently in greater detail. Thedistal catch members 240 may have sufficient resilience to permit theprimary plunger 50 to pass through the locking mechanism in a distal direction, but to deflect outwardly and prevent proximal movement of theprimary plunger 50, as will be described. - In the embodiment of
FIGS. 11-15 , thedistal catch members 240 are configured aslong catches 242 andshort catches 246 alternating around the circumference of thebody portion 235 at the distal end of thebody portion 235. Thelong catches 242 include long-catch ends 244 angled slightly inwardly (i.e., toward the longitudinal axis 1 (seeFIG. 11 )) of the sleeved locking dual-stage syringe 200. Theshort catches 246 include short-catch ends 248 also angled slightly inwardly. The lengths of thelong catches 242 define adistal stop level 243. Likewise, the lengths of theshort catches 246 define aproximal stop level 247. As will be described in greater detail subsequently, thedistal stop level 243 and theproximal stop level 247, in turn, define positions, beyond which when theprimary plunger 50 is inserted into theexternal barrel 10 and surrounded by thelocking mechanism 30, proximal movement of theprimary plunger 50 is prevented. - Referring to
FIGS. 16-17 , theprimary plunger 250 is insertable into the lockingsleeve 230. As theprimary plunger 250 is inserted in the distal direction through the lockingsleeve 230, thedistal stop ring 256 and, subsequently, theproximal stop ring 258 passes distally beyond the distal catch members 340 (for example, the long catches 342 and the short catches 346). The distal catch members 340 then deflect inwardly, in turn locking the primary plunger 350 in a manner that prevents proximal withdrawal of the primary plunger 350 beyond a point at which the proximal stop ring 358 would pass in a proximal direction back through the distal catch members 340 (i.e., beyond the long-catch ends 44). In other embodiments, thedistal catch members 240 may be catches of varying lengths around the circumference of thebody portion 235 at the distal end of thebody portion 235. In other embodiments, thelong catches 242 include long-catch ends 244 that may be angled slightly outwardly (i.e., away from the longitudinal axis 1 (seeFIG. 11 )) of the sleeved locking dual-stage syringe 200. In further embodiments, theshort catches 246 include short-catch ends 248 that may be angled slightly outwardly. - Referring to
FIG. 18 , thesecondary plunger 70 may include anelongated portion 74, ahandle portion 75, and asecondary seal 80. Theelongated portion 74 of thesecondary plunger 70 may includeribbed members 76 perpendicular to theelongated portion 74 to provide stability to theelongated portion 74 and facilitate insertion of thesecondary plunger 70 into thesecondary chamber 95 of theprimary plunger 50. Thesecondary plunger 70 may include aninsertion stop 72 that defines a maximum extent to which thesecondary plunger 70 may be inserted into thesecondary chamber 95 of theprimary plunger 50. It should be understood that theinsertion stop 72, theelongated portion 74, thehandle portion 75, and ribbed members 76 (if any), may have various shapes, sizes, or configurations and are not limited to the specific configuration ofFIG. 18 . - The primary components of the dual-stage syringes having sleeved locking
mechanisms 200 have been described, along with general operating principles of the lockingsleeve 230. The primary components and the general operating principles result in at least five operational stages of the dual-stage syringes having sleeved lockingmechanisms 200, each of which now will be described with reference toFIGS. 19-29 . In particular, the operational stages include a shipped configuration (FIGS. 19-21 ), a flushed configuration (FIGS. 22-23 ), a punctured configuration (FIGS. 24-25 ), a primed configuration (FIGS. 26-27 ), and a delivery configuration (FIGS. 28-29 ). It should be understood that description with regard to these operational stages is intended to illustrate one manner of operating the sleeved locking dual-stage syringe 200 and, through illustrating one manner of operating the sleeved locking dual-stage syringe 200, to further elucidate the functions and synergies of the primary components of the sleeved locking dual-stage syringe 200. - In embodiments, the shipped configuration of
FIGS. 19-21 of the sleeved locking dual-stage syringe 200 is a configuration in which the sleeved locking dual-stage syringe 200 may be received by a qualified medical practitioner intending to incorporate the sleeved locking dual-stage syringe 200 into a delivery system for a procedure such as radioembolization. In the shipped configuration, thelocking mechanism 230, theprimary plunger 250, and thesecondary plunger 270 all are inserted to varying extents into theexternal barrel 210. In particular, thelocking mechanism 230 is fully inserted into theexternal barrel 210 so that theproximal ridge 232 is seated in the external proximal opening 211 of theexternal barrel 210. Theprimary plunger 250 is only partially inserted into theexternal barrel 210, such that some amount of theplunger body portion 255 remains outside theexternal barrel 210. Furthermore, theprimary plunger 250 is inserted only sufficiently far through the locking mechanism, such that thedistal stop ring 256 has not passed distally beyond the long-catch ends 244 of thelong catches 242 of thelocking mechanism 230. - In the shipped configuration of the sleeved locking dual-
stage syringe 200, the portion of theprimary chamber 290 not filled by theprimary plunger 250 initially contains a fluid such as saline, which fluid is intended to flush the system of air at the beginning of the radioembolization procedure. For illustration purposes only, adelivery needle 150 is shown as protruding into theprimary chamber 290. In some embodiments, thedelivery needle 150 may be attached to the sleeved locking dual-stage syringe 200 in the shipped configuration. In other embodiments thedelivery needle 150 may be a component of a delivery system. Some embodiments may include adistal fixture 5. In some embodiments,distal feature 5 may be a gasket, which seals the externaldistal opening 217 of theexternal barrel 210 to prevent fluidic communication between theprimary chamber 290 and the outside of theexternal barrel 210, except through thedelivery needle 150. In other embodiments,distal feature 5 may be a luer connection, which may be used to connect a the locking dual-stage syringe 200 to a delivery device. In further embodiments, the luer connection may be a male luer connection that has a corresponding female luer connection on a delivery device. In other embodiments, thedistal feature 5 may be another connection feature, such as a slip fit, a needless connection port, or any other connection suitable for attachment to a delivery device. - In the shipped configuration of the sleeved locking dual-
stage syringe 200, thesecondary plunger 270 is inserted into thesecondary chamber 295 to such an extent that theinsertion stop 272 abuts theproximal wing portion 251 of theprimary plunger 250. The portion of thesecondary chamber 295 that is not occupied by thesecondary plunger 270 is filled with radioembolization beads (not shown). The radioembolization beads are sealed within the secondary chamber by theplunger seal 260. No fluidic communication exists between theprimary chamber 290 and thesecondary chamber 295. - In embodiments, on receiving a sleeved locking dual-
stage syringe 200 in the shipped configuration and optionally attaching the sleeved locking dual-stage syringe 200 to an appropriate delivery system including a reservoir (not shown) that is fluidically connected to thedelivery needle 150, the practitioner may pull thesecondary plunger 270 proximally to cause both theprimary plunger 250 and thesecondary plunger 70 to move proximally, thereby expanding theprimary chamber 290 and drawing the fluid in the reservoir into theprimary chamber 290 by suction force. The practitioner may then push the secondary plunger distally to force the fluid in theprimary chamber 290 back toward the reservoir and place the sleeved locking dual-stage syringe 200 into the flushed configuration. - In embodiments, in the flushed configuration of
FIGS. 22-23 of the sleeved locking dual-stage syringe 200, theproximal stop ring 258 has passed the short-catch ends 248 and is substantially even with the long-catch ends 244 but has not passed the long-catch ends 244 in a distal direction. As theproximal stop ring 258 passes the short-catch ends, the short-catch ends 248 may snap inwardly with an audible click to inform the practitioner that the flushed configuration has been reached. Once the audible click has been heard, the primary plunger cannot move proximally beyond the point at which the short-catch ends 48 abut against theproximal stop ring 258. In the flushed configuration of the sleeved locking dual-stage syringe 200, thedelivery needle 150 has not pierced through theplunger seal 260 of theprimary plunger 250. However, by continued movement of theprimary plunger 250 in the distal direction, sleeved locking dual-stage syringe 200 reaches the punctured configuration so that mixing of the radioembolization beads in thesecondary chamber 295 of theprimary plunger 250 with fluids forced into the reservoir of the delivery system may commence. - In embodiments, in the punctured configuration of
FIGS. 24-25 of the sleeved locking dual-stage syringe 200, theprimary plunger 250 has been inserted to its fullest extent into theexternal barrel 210, whereby thedelivery needle 150 pierces through theplunger seal 260 and a piercingend 155 of thedelivery needle 150 is disposed within thesecondary chamber 295 containing the radioembolization beads. Furthermore, as the punctured configuration is reached, theproximal stop ring 258 passes the long-catch ends 244 of thelocking mechanism 230. In turn, the long-catch ends 244 deflect inwardly by their resilience, resulting in a second audible click to inform the practitioner that the punctured configuration has been reached and thesecondary chamber 295 is in fluidic communication with the reservoir of the delivery system outside the sleeved locking dual-stage syringe 100. Accordingly, theprimary plunger 250 is locked a second time and proximal movement of theprimary plunger 250 is completely prevented. - Once the punctured configuration has been attained during the procedure, the practitioner may unlock the
secondary plunger 270, for example, by rotating thesecondary plunger 270. The practitioner then may pull thesecondary plunger 270 in the proximal direction to expand thesecondary chamber 295 and draw fluid from the reservoir of the delivery system into thesecondary chamber 295 to be intimately mixed with the radioembolization beads in thesecondary chamber 295. When thesecondary plunger 270 is pulled proximally to its maximum extent, without removing thesecondary plunger 270 from thesecondary chamber 295, the sleeved locking dual-stage syringe 200 is in the primed configuration. - In some embodiments, in the primed configuration of
FIGS. 26-27 of the sleeved locking dual-stage syringe 200, thesecondary chamber 295 has its maximum volume and contains a treatment mixture such as a mixture of radioembolization beads, for example and an appropriate carrier fluid such as saline, for example. This mixture is the delivery mixture, ready for injection into the patient. - In embodiments, in the delivery configuration of
FIGS. 28-29 of the sleeved locking dual-stage syringe 200, the practitioner pushes thesecondary plunger 270 in the distal direction to expel the delivery mixture, created when the sleeved locking dual-stage syringe 200 was placed into the primed configuration previously described, distally through thedelivery needle 150 and into a delivery system for injection into the patient. The abutting of theinsertion stop 272 of thesecondary plunger 270 against theproximal wing portion 251 of theprimary plunger 250 signals to the practitioner that thesecondary plunger 270 has been fully depressed and the dosing of the delivery mixture is complete. Alternatively, the practitioner may pump thesecondary plunger 270 multiple times to accomplish multiple cycles of refilling thesecondary chamber 295 with fluid and expelling the contents of thesecondary chamber 295, so as to ensure that the full dosing of the radioembolization beads has been sent to the delivery system. - Having described embodiments of the sleeved locking dual-
stage syringe 200 in detail, embodiments of a turn-key locking dual-stage syringe 400 will now be described with reference toFIGS. 30-32 . Individual components of an embodiment of a turn-key locking dual-stage syringe 400 have previously been described, including theexternal barrel 410 and theprimary plunger 450. - As shown in
FIG. 30 , an exemplary embodiment of the turn-key locking dual-stage syringe 400 fully assembled includes anexternal barrel 410, a primary plunger 450 (accommodated within the external barrel 410), and asecondary plunger 470. - By way of comparison with embodiments of dual-stage syringes having sleeved locking mechanisms, in place of the locking
sleeve 230 of the sleeved locking dual-stage syringe 200 previously described, the turn-key locking dual-stage syringe 400 includes a turn-key locking mechanism. As shown in the embodiment exemplified inFIGS. 30-32 the turn key locking mechanism may include an initial-stage track 412, a intermediate-stage track 414, and a final-stage track 416 within theexternal barrel 410. In other embodiments, the turn-key locking dual-stage syringe 400 may include one or more additional tracks Like the sleeved locking dual-stage syringe 200 previously described, the turn-key locking dual-stage syringe 400 may include any of the polymers, plastics, metals, or alloys listed above, or it may include other materials such as nylon. Referring now toFIG. 10 , embodiments of aprimary plunger 450 includes male features 465, which are shaped and sized appropriately to correspond the female features of the turn-key locking mechanism ofFIG. 5 , previously described. In embodimentsmale features 465 may be shaped and sized appropriately to travel within thetracks external barrel 410. - The intersection of the initial-
stage track 412 with the 414 corresponds to an initial stage of the primary plunger. The intersection of the initial-stage track 412 with the intermediate-stage track 414 corresponds to a position of theprimary plunger 450 analogous to the flushed configuration of the sleeved locking dual-stage syringe 200, described previously. In the initial stage, the primary plunger is inserted proximal to the initial-stage track 412 and may be freely movable distally or proximally. The intermediate-stage track 414 corresponds to an intermediate stage of the primary plunger. In the intermediate stage, the primary plunger may traverse the intermediate-stage track and is prevented from moving proximally beyond the intermediate-stage track. The physician rotates thesecondary plunger 470 to shift the male features 465 across the intermediate-stage track 414 and prepare the turn-key locking dual-stage syringe 400 to enter the delivery configuration. The intersection of the final-stage track 416 with the intermediate-stage track 414 corresponds to a final stage of the primary plunger. A final push of thesecondary plunger 470 in a distal direction causes the male features 465 to slide down the final-stage track 416 sufficiently far to cause a delivery needle to pierce thesecondary seal 80 of theprimary plunger 450. In the final stage, the primary plunger is inserted distal to the intermediate-stage track and is prevented from moving proximally beyond a distal end of the final-stage track. In other embodiments, the turn-key locking dual-stage syringe 400 may include a turn-key locking mechanism that includes one or more additional tracks in the surface of theexternal barrel 410, which may define one or more additional stages. - In some embodiments, the dual-stage syringes described herein include integrated one-way valve dual-stage syringe. In some embodiments, the integrated one-way valve dual-stage syringe may be a dual-stage syringe having an integrated one way valve and needle. and needle. In some embodiments, the integrated one-way valve dual-stage syringe may be a dual-stage syringe having two integrated one way valves. Embodiments of the integrated one-way valve dual-stage syringe may be used in any technical setting where it is necessary to delivery two separate and isolated mediums, such as during Transarterial Radioembolization for the treatment of malignant liver tumors.
- Referring now to
FIGS. 33-36C , embodiments of the integrated one-way valve dual-stage syringe 600 are provided. In some embodiments, the integrated one-way valve dual-stage syringe 600 may include aprimary plunger 650, which may be configured to deliver at least two media independently. - Referring to
FIGS. 33 and 35 , an integrated one-way valve dual-stage syringe 600 is provided according to embodiments. In the embodiment exemplified inFIG. 33 , the integrated one-way valve dual-stage syringe 600 may include anexternal barrel 610, which accommodates aprimary plunger 650. Theexternal barrel 610 may have aprimary chamber 690 defined through theexternal barrel 610 from a proximal opening of theexternal barrel 610 to adistal opening 619 of theexternal barrel 610. In embodiments, a floatingseptum plunger 674 may be disposed within theprimary chamber 690 of theexternal barrel 610. In embodiments, adivider 672 may be disposed within theprimary chamber 690 of theexternal barrel 610, which divides thesecondary chamber 606 to theprimary chamber 690. - In embodiments, the
external barrel 610 may be made of various materials such as, for example, polymers, plastics, or metals. Non-limiting example polymers for the external barrel include polycarbonates (PC), polyethylenes (PE), polyethylene terephthalates (PET). Non-limiting example plastics for theexternal barrel 610 include poly(methyl methacrylate) (PMMA) and composite resins such as polycarbonate loaded with tungsten. Non-limiting example metals and metal alloys for theexternal barrel 610 include stainless steel, lead, copper, tungsten, aluminum, pewter, and various alloys of any of these. In some embodiments, theexternal barrel 610 is made of a radiation shielding material such as the plastics or metals previously listed. The radiation shielding material may have a thickness sufficient to ensure that radiation from a radioactive therapeutic material in the integrated one-way valve dual-stage syringe 600 cannot penetrate to the environment or cause safety concerns for personnel operating the integrated one-way valve dual-stage syringe 600. In embodiments, suitable radiation shielding materials may shield operators of the integrated one-way valve dual-stage syringe 600 from beta-particle radiation, from x-rays, or both. - Referring still now to
FIGS. 33 and 35 , theexternal barrel 610 may include an externalproximal opening 611, an externaldistal opening 619 opposite the externalproximal opening 611, and abody portion 615 between the externalproximal opening 611 and the externaldistal opening 619. - Some embodiments of the integrated one-way valve dual-
stage syringe 600 may include one or more locking mechanisms, such as those described previously. For example, the integrated one-way valve dual-stage syringe 600 may include a locking sleeve. An example of an integrated one-way valve dual-stage syringe 600 that includes a lockingsleeve 630 is provided inFIGS. 33 and 36 . Lockingsleeve 630 may be similar to lockingsleeve 230. As such, like lockingsleeve 230, lockingsleeve 630 which may include distal catch members are configured as long catches and short catches alternating around the circumference of the body portion at the distal end of the lockingsleeve 630. In further embodiments, the one ormore locking mechanisms 630 may allow for greater delivery control and may provide tactile and audio feedback for assurance of when media are changed. In embodiments, the locking mechanisms of the integrated one-way valve dual-stage syringe 600 may be temporary or permanent. - Referring still now to
FIGS. 33 and 35 , the integrated one-way valve dual-stage syringe 600 may include aprimary plunger 650 of the locking-mechanism dual-stage syringe 100. Theprimary plunger 650 may have a sealeddistal end 604 that defines asecondary chamber 606. In embodiments, theprimary plunger 650 may be sufficiently narrow to be accommodated byexternal barrel 610. The primary plunger 650is may engage thesecondary chamber 606 and cause thesecondary chamber 606 to function as a plunger to theexternal barrel 610. This may assure that little or no pressure may be applied to the medium in thesecondary chamber 606 during the actuation of theexternal barrel 610. - In embodiments, the
primary plunger 650 may be made of various materials such as, for example, polymers, plastics, or metals. Non-limiting example polymers for the external barrel include polycarbonates (PC), polyethylenes (PE), polyethylene terephthalates (PET). Non-limiting example plastics for theprimary plunger 650 include poly(methyl methacrylate) (PMMA) and composite resins such as polycarbonate loaded with tungsten. Non-limiting example metals and metal alloys for theprimary plunger 650 include stainless steel, lead, copper, tungsten, aluminum, pewter, and various alloys of any of these. In some embodiments, theprimary plunger 650 is made of a radiation shielding material such as the plastics or metals previously listed. The radiation shielding material may have a thickness sufficient to ensure that radiation from a radioactive therapeutic material in the integrated one-way valve dual-stage syringe 600 cannot penetrate to the environment or cause safety concerns for personnel operating integrated one-way valve dual-stage syringe 600. In embodiments, suitable radiation shielding materials may shield operators of the integrated one-way valve dual-stage syringe 600 from beta-particle radiation, from x-rays, or both. - Embodiments of the integrated one-way valve dual-
stage syringe 600 may include a one-way valve 682, which is configured to allow flow in only one direction, which may be from thesecondary chamber 606 to theprimary chamber 690. One-way valve 682 may allow for a medium in asecondary chamber 606 to be mixed with fluid from theprimary chamber 690. In further embodiments, the integrated one-way valve dual-stage syringe 600 may allow for a medium in asecondary chamber 606 to be mixed with fluid from theprimary chamber 690 multiple times and for theprimary chamber 690 to be purged multiple times. In particular, the integrated one-way valve dual-stage syringe 600 may include one or more additional one-way valves, which are each configured to allow flow in only one direction. In particular, the one-way valves may allow for a flow path that mixes the media contained in theprimary chamber 690 with the media in thesecondary chamber 606 while eliminating the need for secondary or external connections, such as secondary or external connections with one or more additional syringes. In embodiments, the number and sizes of the chambers can vary. - Referring now to
FIG. 33 , in some embodiments, the integrated one-way valve dual-stage syringe 600 may include and aneedle 150 that passes through the floatingseptum plunger 674 and into theprimary chamber 690. This embodiment may include a oneway valve 681 at the distal end of theneedle 150. InFIG. 33 , thedivider 672 may include aport 673. In some embodiments, theport 673 may be aligned with theneedle 150. In other embodiments, theprimary plunger 650, theexternal barrel 610, or other component may be rotated in order to align theport 673 with theneedle 150. -
FIGS. 34A, 34B, and 34C exemplify operation of the embodiment of the integrated one-way valve dual-stage syringe 600FIG. 33 . InFIG. 34A , theprimary plunger 650 is advanced distally, which advances thesecondary chamber 606 and sealeddistal end 604 distally. InFIG. 34B , a first lock of the lockingsleeve 630 may be engaged, and the barrel may be rotated to engage a second lock of the lockingsleeve 630 and align theneedle 150 and the sealedport 673. InFIG. 34C , a second lock of the lockingsleeve 630 may be engaged, and theneedle 150 may puncture theport 673. InFIG. 34C , media from theprimary chamber 690 may flow from theprimary chamber 690 through the one-way valve 682, into thesecondary chamber 606 to be mixed with fluid from theprimary chamber 690. The mixed fluid may then flow through theport 673 through thehollow needle 150, through the oneway valve 681, and out the externaldistal opening 619. - Referring now to
FIG. 35 , in some embodiments, the integrated one-way valve dual-stage syringe 600 may include a one-way valve 683 on one side of theexternal barrel 610, which may be allow flow from thesecondary chamber 606 to achannel 627 disposed within thesidewall 629 of theexternal barrel 610. -
FIGS. 36A, 36B, and 36C exemplify operation of the embodiment of the integrated one-way valve dual-stage syringe 600FIG. 35 . InFIG. 35A , theprimary plunger 650 is advanced distally, which advances thesecondary chamber 606 and sealeddistal end 604 distally. InFIG. 34B , a first lock of the lockingsleeve 630 may be engaged, and the barrel may be rotated to engage a second lock of the lockingsleeve 630 and align an opening 677 (seeFIG. 35 ) with the one-way valve 683. InFIG. 34C , a second lock of the lockingsleeve 630 may be engaged, and the one-way valve 683 may be aligned so that thesecondary chamber 606 is in fluid communication thechannel 627 disposed within thesidewall 629 of theexternal barrel 610. InFIG. 34C , media from theprimary chamber 690 may flow from theprimary chamber 690 through the one-way valve 682, into thesecondary chamber 606 to be mixed with fluid from theprimary chamber 690. The mixed fluid may then flow through the one-way valve 683, through thechannel 627 through the oneway valve 681, and out the externaldistal opening 619. - In embodiments, the integrated one-way valve dual-
stage syringe 600 comprise any biocompatible material such as metals, metal alloys, and polymers. In some embodiments, the integrated one-way valve dual-stage syringe 600 may include polymers such as polycarbonate, polyethylene, and polyethylene terephthalate. In some embodiments, the integrated one-way valve dual-stage syringe 600 may include seals made from any suitable material, such as thermoplastic elastomers, thermoplastic vulcanizates, silicone. In some embodiments, the integrated one-way valve dual-stage syringe 600 may include metals, such as lead, stainless steel, and copper. In other embodiments, the integrated one-way valve dual-stage syringe 600 may be overmolded a material such as thermoplastic elastomers, thermoplastic vulcanizates, or silicone, for example. - In embodiments of the dual-stages syringes described herein, which may include locking-mechanism dual-stage syringes and dual-stage syringes having integrated one-way valves, the one or more safety features may include a distal feature 5 (see
FIG. 21 ), such a gasket, luer connection, slip fit, a needless connection port, or any other connection suitable for attachment to a delivery device. For example, embodiments of the dual-stages syringes described herein, which may include locking-mechanism dual-stage syringes and dual-stage syringes having integrated one-way valves, may include a gasket similar todistal feature 5 ofFIG. 21 , which seals an external distal opening of the external barrel to prevent fluidic communication between the primary chamber and the outside of the external barrel, except through the delivery needle. Other embodiments of the dual-stages syringes described herein, which may include locking-mechanism dual-stage syringes and dual-stage syringes having integrated one-way valves, may include a luer connection, similar to distal feature 5 (seeFIG. 21 ), which may be used for connection to a delivery device. In further embodiments, the luer connection may be a male luer connection that has a corresponding female luer connection on a delivery device. In other embodiments, thedistal feature 5 may be another connection feature, such as a slip fit, a needless connection port, or any other connection suitable for attachment to a delivery device. - In embodiments of the dual-stages syringes described herein, which may include locking-mechanism dual-stage syringes and dual-stage syringes having integrated one-way valves, the dual-stage syringes may include one or more safety features, which may contribute to making embodiments of the dual-stage syringes describe herein suitable for safe and effective delivery of hazardous therapeutic materials. As will be subsequently described in more detail, safety features that may be optionally incorporated into embodiments of the dual-stage syringes described herein may include membrane technology, safety tabs, telemeterized syringe plunger caps, needle features, magnetic walls, and combinations thereof. In some embodiments, referring now to
FIG. 4 , thedistal end 19 may be sealed with a removeable or puncturable material. Similarly, the distal end 419 (seeFIG. 5 ) and the distal end 610 (seeFIGS. 33, 35 ) may be sealed with a removeable or puncturable material. - In embodiments of the dual-stages syringes described herein, which may include locking-mechanism dual-stage syringes and dual-stage syringes having integrated one-way valves, the one or more safety features may include a relief valve or vent, which may serve to relieve pressure from within the syringe, for example, when the primary plunger is distally advanced. In some embodiments, the relief valve or
vent 3 may be integrated into the distal end of the external barrel, as shown inFIG. 21 . - Referring now to
FIG. 37 , in embodiments of the dual-stage syringes described herein, which may include locking-mechanism dual-stage syringes and dual-stage syringes having integrated one-way valves, the dual-stage syringe may optionally includemembrane technology 800 to facilitate purging of air from the system. As shown inFIG. 37 , an exemplary embodiment includes a sleeved locking dual-stage syringe 200 in the punctured configuration in fluidic communication withmembrane technology 800. In some embodiments, themembrane technology 800 may include components that work together to form dry, leakproof connections, airtight expansion chambers that reduce surface contamination and prevent microbial ingress. In further embodiments, the membrane technology components may be adapted to standards that are compatible with all standard sizes of hazardous drug vials and intravenous connections and tubing. - Referring now to
FIGS. 38-39 , in embodiments of the dual-stage syringes described herein, which may include locking-mechanism dual-stage syringes and dual-stage syringes having integrated one-way valves, the dual-stage syringe may optionally include aratcheting safety tab 900 to help mix or suspend pharmaceuticals and particles in a defined volume of solution. - In the context of radioembolization, radioactive particles, such as microspheres, can be transported to a medical facility in a prefilled syringe, such as embodiments of the dual-stages syringes described herein. During this time, the radioactive particles may settle at the bottom of the syringe. Therefore, it is required for the medical professional to draw up a given amount of saline into the syringe to help re-suspend the particles so that the therapeutic fluid comprising the particles has the appropriate concentration for effective delivery. If this suspension is not performed, there may be a risk of the particles either being delivered in a large bolus to the patient and/or there is a risk that the large bolus may clog the administrative tubing set, which may result in misadministration.
- Therefore, a ratcheting
safety tab 900 may be incorporated into embodiments of the dual-stages syringes described herein to help mix or suspend pharmaceuticals and particles in a defined volume of solution. Referring now toFIG. 38 , embodiments of aratcheting safety tab 900 may include asafety tab 910, connected at one end ofsafety tab 910 to theprimary plunger 50 by aplunger attachment portion 940, which may include one or moreangled teeth 920 at thedistal end 930 of the ratchetingsafety tab 900. -
FIG. 39 illustrates a cross-sectional side view of aratcheting safety tab 900 configured to an embodiments of the dual-stages syringes described herein. In embodiments, the one or moreangled teeth 920 may engage one or more retention clips attached to theprimary plunger 50. In other embodiments, various mating mechanisms could be used, such as pins and lots, which may engage one or more retention clips attached to theprimary plunger 50. - Referring to
FIG. 39 , as theprimary plunger 50 is pulled proximally, one or moreangled teeth 920 on thetab 910 slide past theretention clip 11. Additionally, as theangled teeth 920 on theratcheting safety tab 900 proximally slide past theretention clip 11, and a hard stop results when an attempt is made to advance theprimary plunger 50 distally. In embodiments, theprimary plunger 50 may be pulled proximally, until each of the one or moreangled teeth 920 on thesafety tab 910 slide past theretention clip 11. In other embodiments, the geometry may be of any configuration such thatprimary plunger 50 must be pulled a predetermined distance before the safetytab safety tab 910 may be removed. Once thesafety tab 910 is removed, theprimary plunger 50 may then be depressed, and the treatment may be administered. In other embodiments, thesafety tab 910 may not need to be removed from theprimary plunger 50 for the treatment to be administered. Once theprimary plunger 50 is pulled beyond the predetermined distance, the user could rotate thesafety tab 910 to an “unlocked” or “delivery” position. Once thesafety tab 910 is unlocked, theprimary plunger 50 may then be depressed, and the treatment may be administered. When thesafety tab 910 is locked, theprimary plunger 50 cannot be depressed, and the treatment cannot be administered. - In embodiments, the ratcheting
safety tab 900 may include any biocompatible material such as metals, metal alloys, and polymers. In some embodiments, the ratchetingsafety tab 900 may include polymers such as polycarbonate, polyethylene, polypropylene and polyethylene terephthalate. In some embodiments, the ratchetingsafety tab 900 may include seals made from any suitable material such as thermoplastic elastomers, thermoplastic vulcanizates, or silicone, for example. In some embodiments, the ratchetingsafety tab 900 may include metals, such as lead, aluminum, stainless steel, and copper. - Referring now to
FIGS. 40A, 40B, and 40C , in some embodiments, the dual-stage syringes described herein may include a telemeterizedsyringe plunger cap 1000. - During transarterial radioembolization procedures, changes in injection pressure and flow rate can impact the safety, efficacy, and patient comfort of medical devices and systems. As stated previously, for example, liver cancer can be treated with embolizing beads in conjunction with chemotherapy. In this scenario, the vasculature has been structurally wakened from chemotherapy. Thus, the injection pressure the physician can safely use may be limited. However, the efficacy and dispersion of embolizing beads is correlated with increased injection pressure and flow rates.
- Therefore, in some embodiments, the dual-stage syringes described herein may include a telemeterized
syringe plunger cap 1000, which may monitor and record the injection pressure and flow rate of the embolizing beads delivered from the dual-stage syringe and allow for the desired dispersion to be achieved without damaging the vasculature. In embodiments, a telemeterized syringe plunger cap may provide real-time feedback to the medical professional, and the resulting data could be correlated to patience outcomes, serve for quantitate training, and provide inputs to automated systems and ergonomic devices. In some embodiments, one or more of a pressure sensor and/or a displacement sensor of a telemeterized syringe plunger cap may sense a corresponding movement of the syringe plunger as a sensed plunger movement; when the syringe plunger is translationally moved in a translational direction, such that movement in the translational direction one of proximally or distally advances the syringe plunger. In embodiments, this then generates via the one or more of a pressure sensor and a displacement sensor of the telemeterized syringe plunger cap, one or more output signals based on the sensed plunger movement. This then generates, via a processor, at least one of a flow rate of the administered fluid, a flow amount of the administered fluid, a pressure of the administered fluid, a pressure applied to the syringe plunger, or the translational direction of movement of the syringe plunger with respect to the syringe based on the one or more output signals. In some embodiments, at least one of the flow rate of the administered fluid, the flow amount of the administered fluid, the pressure of the administered fluid, or the translational direction of movement of the syringe plunger with respect to the syringe may be displayed on a display communicatively coupled to the syringe. -
FIG. 40A shows a top view of a telemeterizedsyringe plunger cap 1000. In embodiments, the telemeteredsyringe plunger cap 1000 may include awireless transmitter 1008, apressure sensor 1005 anddisplacement sensor 1001 housed in a cap that attaches to the proximal end of a plunger or asyringe 100.FIG. 40B shows a section view along A-A shown inFIG. 40A .FIG. 40C shows the telemeterizedsyringe plunger cap 1000 attached to the proximal end of a plunger or asyringe 100. In other embodiments, the mechanism for engagement between the telemeterizedsyringe plunger cap 1000 and thesyringe 100 may be, for example, mechanical, chemical, or magnetic. In some embodiments, thewireless transmitter 1008 may be a Bluetooth transmitter. In some embodiments, thedisplacement sensor 1001 may include an accelerometer. In some embodiments, the cap may be made from polyethylene. - In an exemplary embodiment, the telemeterized
syringe plunger cap 1000 may be attached to the proximal end of a plunger or a syringe 100that contains radioactive materials, such as microspheres. As the physician applies pressure to the top of the syringe, the telemeterizedsyringe plunger cap 1000 will deflect, and the pressure will be measured by theinternal pressure sensor 1005. As thesyringe 100 translates forward, thedisplacement sensor 1001 will register the motion. The information from both thepressure sensor 1005 and thedisplacement sensor 1001 may be wirelessly transmitted in real time to a computer or smart device where the information may be viewed and stored. Once the procedure has been completed, the telemeterizedsyringe plunger cap 1000 may be discarded or recovered for sterilization and reuse. In some embodiments, the telemeterizedsyringe plunger cap 1000 may communicate with other devices by various communication means including Bluetooth, WiFi, and wired connections. - In other embodiments, the telemeterized
syringe plunger cap 1000 may include any number of sensors of varying types, such as capacitance sensors, resistance sensors, laser sensors, and optical sensors, which may produce the same outputs previously described. In other embodiments, the telemeterizedsyringe plunger cap 1000 may include any number of sensors of varying types, such as RFID tags and temperature sensors, which may produce additional outputs or labeling. In some embodiments, additional sensors may be added to monitor withdraw forces, pressures, or rates. - The telemeterized
syringe plunger cap 1000 may include different display modalities, such as LED, projection, and tactile display modalities. In other embodiments, the telemeterizedsyringe plunger cap 1000 may include alarm features, such as flashing lights, sounds, vibrations. - In embodiments, the telemeterized
syringe plunger cap 1000 may include any biocompatible material such as metals, metal alloys, and polymers. In some embodiments, the telemeterizedsyringe plunger cap 1000 may include polymers such as polycarbonate, polyethylene, polypropylene and polyethylene terephthalate. In some embodiments, the telemeterizedsyringe plunger cap 1000 may include seals made from any suitable material such as thermoplastic elastomers, thermoplastic vulcanizates, silicone. In some embodiments the telemeterizedsyringe plunger cap 1000 may include polyoxymethylene and acrylonitrile butadiene styrene. In some embodiments, the telemeterizedsyringe plunger cap 1000 may include metals, such as lead, aluminum, stainless steel, and copper. - In some embodiments, the
external barrel 10 of embodiments of the dual-stage syringes described herein may include one or more needles that may be attached to or mounted on the external barrel near the externaldistal opening 19 of theexternal barrel 10. - In some embodiments, a magnetic component may be incorporated into one or more individual components of the dual-stage syringes so that the magnetic components such individual components may produce one or more magnetic fields. For example, in some embodiments, the primary plunger may include one or more magnetic components. Referring back to
FIG. 7 , theprimary plunger 50 may have a secondary chamber defined through theprimary plunger 50 from a proximal opening of theprimary plunger 50 to a sealed distal end of theprimary plunger 50. Theprimary plunger 50 may include one or more magnetic components in theplunger body portion 55 so that the magnetic components included in theplunger body portion 55 may produce a magnetic field. As subsequently described in more detail, the one or more magnetic components may produce a magnetic field that repels a diamagnetic material of a plurality of microspheres. This repulsion between the one or more magnetic components and the diamagnetic material of the plurality of microspheres may cause the plurality of microspheres to levitate within embodiments of the dual-stage syringe. As a result, the magnetic components incorporated into embodiments of the dual-stage syringes described herein may reduce interaction or binding of radiotherapeutic microspheres with the dual-stage syringes, which may prevent browning and/or embrittlement of the materials used to form embodiments of the dual-stage syringes described herein. Additionally, in some embodiments, the magnetic components incorporated into components of the dual-stage syringes described herein may produce non-uniform magnetic fields, for example, along theplunger body portion 55 of theprimary plunger 50, which may facilitate the mixing of radiotherapeutic microspheres in a suspension medium such as saline. - In embodiments, the dual-stage syringes may include any suitable gamma compatible material. A gamma compatible material may be any radiation-stable, medical-grade polymer material. The radiation stability of the gamma compatible material may be dependent on the tolerance level of the particular type of medical grade polymer material. Once the container material absorbs a radiation dose that exceeds the container material's tolerance level, browning or embrittlement of the dual-stage syringe may occur. Exemplary gamma compatible materials include, but are not limited to, thermoplastics, including acrylonitrile/butadiene/styrene, aromatic polyesters, cellulosics, fluoropolymers, polyacetals, polyacrylics, polyamides, polyethylenes polyimides, polymethylpentene, polyphenylene sulfide, polypropylenes, polystyrenes, polysulfones, polyurethanes, polyvinylbutyral, polyvinylchloride, polyvinylidene chloride, styrene/acrylonitrile; thermosets including allyl digylcol carbonate, epoxies, phenolics, polyesters, polyurethanes, and elastomers including butyl, ethylene-propylene diene monomer, fluoro elastomers, natural rubbers, nitriles, polyacrylics, polychloroprenes, silicones, styrene-butadienes, and urethanes. The radiation tolerance of the elastomers may be affected by the base polymer and the curing system used. In some embodiments, the dual-stage syringe may be made from a gamma compatible material with a tolerance level of from about 5 kGy to about 100,000 kGy, from about 5 kGy to about 10,000 kGy, from about 5 kGy to about 5,000 kGy, from about 5 kGy to about 1,000 kGy, from about 5 kGy to about 500 kGy, from about 5 kGy to about 100 kGy, from about 100 kGy to about 100,000 kGy, from about 100 kGy to about 10,000 kGy, from about 100 kGy to about 5,000 kGy, from about 100 kGy to about 1,000 kGy, from about 100 kGy to about 500 kGy, from about 500 kGy to about 100,000 kGy, from about 500 kGy to about 10,000 kGy, from about 500 kGy to about 5,000 kGy, from about 500 kGy to about 1,000 kGy, from about 1,000 kGy to about 100,000 kGy, from about 1,000 kGy to about 10,000 kGy, from about 1,000 kGy to about 5,000 kGy, from about 5,000 kGy to about 100,000 kGy, from about 5,000 kGy to about 10,000 kGy, or from about 10,000 kGy to about 100,000 kGy.
- In embodiments, the dual-stage syringe may include one or more magnetic fields. The one or more magnetic fields of the dual-stage syringe may interact with the plurality of microspheres in a manner that prevents direct contact of the plurality of microspheres to the dual-stage syringe. In some embodiments, the one or more magnetic fields of the dual-stage syringe may interact with the plurality of microspheres in a manner that facilitates mixing of the plurality of microbeads. The mixing may, at least in part, be facilitated by the shape of the dual-stage syringe. In embodiments, the strength, location, and pattern of the one or more magnetic fields of the dual-stage syringe may vary. The magnetic fields may be of sufficient magnitude to levitate or repel the plurality of microspheres off the surface of the dual-stage syringe. This magnitude may be depend on various factors, including the radiation tolerance of the materials included in the dual-stage syringe; the amount of therapeutic agent in the microsphere, more specifically, the amount of radiotherapeutic material in the microsphere; the type of therapeutic agent in the microsphere, more specifically, the amount of radiotherapeutic material in the microsphere; the amount (mass) of microsphere material, the type of microsphere material, the amount (mass) of diamagnetic material in the microsphere, the type of diamagnetic material in the microsphere, and combinations of these factors. The magnetic fields may be of sufficient magnitude to levitate or repel the plurality of microspheres at a height sufficient to prevent browning or embrittlement of the dual-stage syringe. Without being bound by theory, because the dose is reduced by 1/R2, relatively small changes in distance can have a substantial impact on the dose absorbed by the dual-stage syringe.
- In some embodiments, multiple magnetic fields may be present within the dual-stage syringe as a result of magnetic components incorporated within features of the dual-stage syringe. The multiple magnetic fields may have varying strengths. For example, at least a portion of the magnetic fields of the dual-stage syringe may be of a lesser strength, and at least a portion of the magnetic fields of the dual-stage syringe may be of a greater strength. The varying strengths of the magnetic fields of the dual-stage syringe may facilitate mixing of the plurality of microspheres within the dual-stage syringe.
- In embodiments, the magnetic fields of the dual-stage syringe may be produced by incorporating one or more magnetic components into the walls of the dual-stage syringe's individual components. In other embodiments, the magnetic fields of the dual-stage syringe may be produced by surrounding the dual-stage syringe with one or more magnetic components. When the walls of the containers described herein comprise one or more magnetic components, the walls may comprise any number of individual magnetic components (e.g., one, two, three, four, five, six, seven, or eight or more, etc.). Each magnetic component may be fixed in or on the dual-stage syringe by any suitable method. For example, in some variations one or more magnetic components may be embedded in, adhered to, or friction-fit within the dual-stage syringe by any suitable manufacturing methods, including by painting, over-molding, printing, or gluing the one or more magnetic components onto the dual-stage syringe. In embodiments where one or more magnetic components surround the dual-stage syringe, each magnetic component may not be fixed in or on the dual-stage syringe, so the magnetic fields produced by the magnetic components may be mobile. In further embodiments where one or more magnetic components surround the dual-stage syringe, each magnetic component may be embedded in, adhered to, or friction-fit within a casing, cover, or other external component that surrounds at least a portion of the dual-stage syringe.
- In embodiments, the magnetic component may include a permanent magnet. The magnet may be made of any suitable material capable of generating a magnetic field. In some embodiments, the magnetic components may be permanent magnets made out of ferromagnetic materials. For example, in some variations, the magnetic components may comprise one or more rare-earth magnets, cobalt, gadolinium, iron, nickel, alloys of these metals with or without other metals such as alnico, chemical compounds such as ferrites, or a combination of any of these metals or their alloys. In further embodiments, the rare-earth magnets may include samarium cobalt magnets or neodymium magnets.
- In embodiments, the magnetic component may include an electromagnet. When a magnetic component comprises an electromagnet, the electromagnet may be selectively activated to produce a magnetic field. For example, when embodiments of the dual-stage syringe comprise one or more electromagnets, the electromagnets may be activated before the plurality of microspheres are loaded in the dual-stage syringe; the electromagnets may remain activated during storage of the plurality of microspheres to levitate the plurality of microspheres and keep them from settling in the dual-stage syringe; and then the electromagnets may be deactivated after the plurality of microspheres are removed from the dual-stage syringe or after the radioembolization procedure is complete. When the dual-stage syringe comprises multiple electromagnets, these magnetic components may be independently activated or may be activated as a group. In embodiments, the one or more electromagnets may be selectively activated by an electronic interaction, such as by a battery and a switch or other suitable activating means. In some embodiments, the one or more electromagnets may be selectively activated in a manner to create one or more pulsating magnetic fields. In further embodiments, multiple electromagnets may be selectively activated in a manner to create multiple pulsating magnetic fields with varying magnitudes.
- In embodiments, the dual-stage syringe may include multiple magnetic components. In further embodiments, the multiple magnetic components may be any combination of permanent magnets, ferromagnetic components, or electromagnets. In one exemplary embodiment, only side walls of the dual-stage syringe may include permanent magnets. In these variations, base wall may include only permanent magnets, only ferromagnetic components, only electromagnets, or a mix of some or all of these elements. In the side walls of the dual-stage syringe may include permanent magnets, and the base wall or a lid may include only electromagnets that may be activated after the plurality of microspheres have been loaded into the dual-stage syringe.
- In embodiments, each magnetic component may have any suitable size and shape. For example, each magnetic component may be cylindrical, semi-cylindrical, tube-shaped, box-shaped, planar, spherical, or the like. Generally, the dimensions of the magnetic components may be constrained by size of the dual-stage syringes carrying the magnetic components, which in turn may be constrained by the radioembolization procedure itself. For example, the radioembolization procedure may require a specific dose or delivery device, in which case, the dual-stage syringe may be specifically sized to accommodate said dose or fit within said delivery device. Each magnetic component may have any suitable length. In some embodiments, each magnetic component may have a length of about 5 mm, about 10 mm, about 15 mm, about 20 mm, or each magnetic component may extend along the entire length of one wall of the dual-stage syringe.
-
FIG. 41 is a schematic of anexemplary delivery system 2000 into which the sleeved locking dual-stage syringe 200 may be incorporated. Further exemplary delivery systems include those disclosed in U.S. App. No. [Attorney Docket No. P-18891], entitled “RADIOEMBOLIZATION DELIVERY DEVICE,” filed concurrently with the present disclosure, which application is incorporated herein by reference in its entirety. In theexemplary delivery system 2000, the sleeved locking dual-stage syringe 200 and additional components may be housed within a system housing, as schematically illustrated inFIG. 40 by dotted lines surrounding the components of theexemplary delivery system 2000. In some embodiments, the sleeved locking dual-stage syringe 200 may include geometry (orientation) features that adapt the sleeved locking dual-stage syringe 200 to be received in theexemplary delivery system 2000. Non-limiting examples of geometry features may include features that orient the sleeved locking dual-stage syringe 200 in theexemplary delivery system 2000 or features that lock the sleeved locking dual-stage syringe 200 in place within theexemplary delivery system 2000. - In the
exemplary delivery system 2000, the sleeved locking dual-stage syringe 200 is illustrated in the punctured configuration, at which adelivery needle 150 held in place by aneedle mount 2100 provides fluidic communication between asystem reservoir 2200 and thesecondary chamber 95 of the sleeved locking dual-stage syringe 200. One or more additional fluidic reservoirs 2300 (of which, only one is shown inFIG. 41 for illustrative purposes) may be included in theexemplary delivery system 2000 for adding additional fluids to the delivery mixture formed in the sleeved locking dual-stage syringe 200 as previously described. Thesystem reservoir 2200 and the additionalfluidic reservoirs 2300 may be fluidically coupled to amixing valve 2500 throughcoupling lines delivery valve 2700 through anexit line 2600. Thedelivery valve 2700 may be fluidically coupled to adelivery device 2800 such as a catheter or a microcatheter, for example, which is intravenously fluidically coupled to the patient being treated. - Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure belongs. The terminology used in the description herein is for describing particular embodiments only and is not intended to be limiting. As used in the specification and appended claims, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
- As used herein, the terms “horizontal” and “vertical” are relative terms only, are indicative of a general relative orientation only, and do not necessarily indicate perpendicularity. These terms also may be used for convenience to refer to orientations used in the figures, which orientations are used as a matter of convention only and are not intended as characteristic of the devices shown. The present disclosure and the embodiments thereof to be described herein may be used in any desired orientation. Moreover, horizontal and vertical walls need generally only be intersecting walls, and need not be perpendicular.
- For the purposes of describing and defining the present disclosure it is noted that the term “substantially” is used herein to represent the inherent degree of uncertainty that may be attributed to any quantitative comparison, value, measurement, or other representation. The term “substantially” is used herein also to represent the degree by which a quantitative representation may vary from a stated reference without resulting in a change in the basic function of the subject matter at issue. As such, it is used to represent the inherent degree of uncertainty that may be attributed to any quantitative comparison, value, measurement, or other representation, referring to an arrangement of elements or features that, while in theory would be expected to exhibit exact correspondence or behavior, may in practice embody something slightly less than exact.
- While particular embodiments have been illustrated and described herein, it should be understood that various other changes and modifications may be made without departing from the spirit and scope of the claimed subject matter. Moreover, although various aspects of the claimed subject matter have been described herein, such aspects need not be utilized in combination. It is therefore intended that the appended claims cover all such changes and modifications that are within the scope of the claimed subject matter.
Claims (47)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/056,034 US12011552B2 (en) | 2018-05-18 | 2019-05-17 | Dual-stage syringes for independent delivery of two or more fluids |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862673632P | 2018-05-18 | 2018-05-18 | |
US201862673628P | 2018-05-18 | 2018-05-18 | |
PCT/US2019/032983 WO2019222699A1 (en) | 2018-05-18 | 2019-05-17 | Dual-stage syringes for independent delivery of two or more fluids |
US17/056,034 US12011552B2 (en) | 2018-05-18 | 2019-05-17 | Dual-stage syringes for independent delivery of two or more fluids |
Publications (2)
Publication Number | Publication Date |
---|---|
US20210213301A1 true US20210213301A1 (en) | 2021-07-15 |
US12011552B2 US12011552B2 (en) | 2024-06-18 |
Family
ID=66691078
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/056,034 Active 2041-10-17 US12011552B2 (en) | 2018-05-18 | 2019-05-17 | Dual-stage syringes for independent delivery of two or more fluids |
US17/055,721 Pending US20210205584A1 (en) | 2018-05-18 | 2019-05-17 | Catheter with flaring tip |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/055,721 Pending US20210205584A1 (en) | 2018-05-18 | 2019-05-17 | Catheter with flaring tip |
Country Status (7)
Country | Link |
---|---|
US (2) | US12011552B2 (en) |
EP (2) | EP3794608A1 (en) |
JP (3) | JP7361724B2 (en) |
CN (2) | CN112384988A (en) |
AU (2) | AU2019269701A1 (en) |
IL (2) | IL278811B2 (en) |
WO (1) | WO2019222687A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11179518B2 (en) * | 2020-02-27 | 2021-11-23 | Jubilant Draximage Inc. | Syringe shield assembly for housing and transporting a syringe containing radioactive drug |
US20220112951A1 (en) * | 2020-10-09 | 2022-04-14 | Enplas Corporation | Plunger, instrument, and mold |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113509238A (en) * | 2021-07-19 | 2021-10-19 | 江苏迈得诺医疗集团有限公司 | Thrombus-taking catheter |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6093170A (en) * | 1999-01-28 | 2000-07-25 | Hsu; Kuo-Chi | Structure safety syringe |
US6669671B1 (en) * | 1998-12-22 | 2003-12-30 | Owais Mohammad | Retractable needle with dual locking mechanisms |
US20050267411A1 (en) * | 2004-05-28 | 2005-12-01 | Huang-Chuan Chen | Breakable syringe with a safety sleeve |
US20060258977A1 (en) * | 2005-05-02 | 2006-11-16 | Lee Martin N | Autoflush syringe |
US20100100033A1 (en) * | 2006-10-24 | 2010-04-22 | Control Medical Technology, Llc | Double barrel syringe and handles for use with double barrel syringes |
US20140276039A1 (en) * | 2013-03-13 | 2014-09-18 | Medrad, Inc. | Multiple compartment syringe |
US20200129695A1 (en) * | 2017-06-26 | 2020-04-30 | V.V.T. Med Ltd. | Actuator and device for synchronized injection and aspiration |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4313440A (en) * | 1980-09-08 | 1982-02-02 | Ashley Sheldon J | Multipurpose double barrel syringe and method of manufacture of same |
DE3035290A1 (en) | 1980-09-18 | 1982-04-22 | Wolfgang Dr. Igl | Wound covering esp. as antiadhesive layer for absorbent dressings - by mechanised syringe operation in lead shielded measuring chamber |
US4367738A (en) | 1981-10-28 | 1983-01-11 | Janssen Pharmaceutica Inc. | Pre-filled syringe for abusable drugs |
US5203772A (en) * | 1989-01-09 | 1993-04-20 | Pilot Cardiovascular Systems, Inc. | Steerable medical device |
US5192286A (en) * | 1991-07-26 | 1993-03-09 | Regents Of The University Of California | Method and device for retrieving materials from body lumens |
US5478323A (en) | 1993-04-02 | 1995-12-26 | Eli Lilly And Company | Manifold for injection apparatus |
DE4318101A1 (en) | 1993-06-01 | 1994-12-08 | Sterimed Gmbh | Hose coupling |
US5496284A (en) | 1994-09-27 | 1996-03-05 | Waldenburg; Ottfried | Dual-chamber syringe & method |
US5571085A (en) * | 1995-03-24 | 1996-11-05 | Electro-Catheter Corporation | Steerable open lumen catheter |
US5620427A (en) | 1995-04-27 | 1997-04-15 | David R. Kipp | Luer lock system |
GB9801261D0 (en) | 1998-01-21 | 1998-03-18 | Peters Joseph L | Couplings for medical cannulae |
US6293958B1 (en) * | 1998-07-27 | 2001-09-25 | Acist Medical Systems, Inc. | Catheter having flow diffusing tip |
US6231551B1 (en) * | 1999-03-01 | 2001-05-15 | Coaxia, Inc. | Partial aortic occlusion devices and methods for cerebral perfusion augmentation |
DE19933131A1 (en) | 1999-07-19 | 2001-02-01 | Kasprowicz Stanislaw | Container for storing anti-matter comprises hollow body with one or more inner shells which create inner force field |
US6238374B1 (en) | 1999-08-06 | 2001-05-29 | Proxima Therapeutics, Inc. | Hazardous fluid infuser |
US6793660B2 (en) * | 2001-08-20 | 2004-09-21 | Synthes (U.S.A.) | Threaded syringe for delivery of a bone substitute material |
US6911025B2 (en) | 2002-01-25 | 2005-06-28 | Jms Co., Ltd. | Connector system for sterile connection |
US6723074B1 (en) * | 2002-04-09 | 2004-04-20 | Thor R. Halseth | Sequential delivery syringe |
US6722705B2 (en) | 2002-04-25 | 2004-04-20 | Ab Korkor Medical, Inc. | Medical tubing connector |
US20030212371A1 (en) * | 2002-05-10 | 2003-11-13 | Martin E. Smith | Disposable safety syringe |
EP1554007A2 (en) * | 2002-07-16 | 2005-07-20 | Applied Medical Resources Corporation | Drainage catheter |
US7594903B2 (en) * | 2002-09-25 | 2009-09-29 | Abbott Cardiovascular Systems Inc. | Controlling shaft bending moment and whipping in a tendon deflection or other tendon system |
US20050015048A1 (en) * | 2003-03-12 | 2005-01-20 | Chiu Jessica G. | Infusion treatment agents, catheters, filter devices, and occlusion devices, and use thereof |
JP2006522658A (en) | 2003-04-08 | 2006-10-05 | メドラッド インコーポレーテッド | Fluid transport system, fluid transport device, and method for transporting hazardous fluid |
US20040258614A1 (en) | 2003-06-20 | 2004-12-23 | University Of Maryland, Baltimore | Microparticles for microarterial imaging and radiotherapy |
US20050154353A1 (en) * | 2004-01-09 | 2005-07-14 | Alheidt Thomas A. | Positive displacement flush syringe |
US7727195B2 (en) * | 2004-07-01 | 2010-06-01 | West Pharmaceutical Services, Inc. | Syringe device having venting system |
IL162854A (en) * | 2004-07-04 | 2011-08-31 | Igal Sharon | Syringe assembly |
JP2006017660A (en) | 2004-07-05 | 2006-01-19 | Universal Giken:Kk | Radioactive quantity detecting sensor, method of measuring radioactive quantity using the sensor, and radioactive chemical automatic administration device |
US8357147B2 (en) | 2005-08-17 | 2013-01-22 | Spinal Restoration, Inc. | Method for repairing intervertebral discs |
DE202004012714U1 (en) | 2004-08-12 | 2004-11-04 | Smiths Medical Deutschland Gmbh | Luer lock connector for medical devices |
JP4624821B2 (en) | 2004-11-01 | 2011-02-02 | 安西メディカル株式会社 | Radioactive sample holder |
US7947017B2 (en) | 2004-11-22 | 2011-05-24 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
RU2370286C2 (en) * | 2004-12-21 | 2009-10-20 | Бектон, Дикинсон Энд Компани | Prefabricated syringe with blocker (versions) |
EP2248578B1 (en) | 2005-03-04 | 2012-06-06 | President and Fellows of Harvard College | Method for forming multiple emulsions |
US8048059B2 (en) * | 2005-05-09 | 2011-11-01 | Medical Components, Inc. | Security tip for vascular catheter and method of using same |
JP2008540038A (en) | 2005-05-16 | 2008-11-20 | マリンクロッド・インコーポレイテッド | Radiopharmaceutical pig and portable auto-injector |
US7414254B2 (en) | 2005-06-28 | 2008-08-19 | United Pharmacy Partners, Inc. | Tungsten pig for radio-pharmaceuticals |
US7803139B2 (en) | 2005-07-06 | 2010-09-28 | Icu Medical, Inc. | Medical connector with closeable male luer |
JP2009515609A (en) | 2005-11-15 | 2009-04-16 | グローバル メディセーフ ホールディングス リミテッド | Safety syringe with plunger locking means |
CN101360527A (en) | 2005-11-15 | 2009-02-04 | 麦迪塞弗环球控股有限公司 | Safety syringe with plunger locking means |
US7473918B2 (en) | 2005-12-07 | 2009-01-06 | Vulcan Global Manufacturing Solutions, Inc. | Radiation-shielding container |
US7501179B2 (en) | 2005-12-21 | 2009-03-10 | Boston Scientific Scimed, Inc. | Block copolymer particles |
KR101497734B1 (en) * | 2007-06-12 | 2015-03-02 | 백톤 디킨슨 앤드 컴퍼니 | Syringe assembly including reuse prevention mechanism |
MX2009013639A (en) * | 2007-06-12 | 2010-04-30 | Becton Dickinson Co | Syringe with disabling mechanism. |
FR2917981B1 (en) | 2007-06-28 | 2010-05-28 | Novapten | METHOD AND SYSTEM FOR INJECTING A RADIOACTIVE PRODUCT IN THE BODY OF A PATIENT |
CN101951975B (en) | 2007-09-17 | 2013-06-19 | 萨蒂什·桑达尔 | High precision infusion pumps |
US9107828B2 (en) | 2007-10-05 | 2015-08-18 | Boston Scientific Scimed, Inc. | Multi-component particles for injection and processes for forming the same |
JP5520927B2 (en) | 2008-03-25 | 2014-06-11 | サン−ゴバン パフォーマンス プラスティックス コーポレイション | Connector assembly |
US8940539B2 (en) | 2008-05-14 | 2015-01-27 | Biolyph, L.L.C. | Reagent preparation and dispensing device and methods for the same |
JP5726070B2 (en) | 2008-06-06 | 2015-05-27 | バイエル メディカル ケア インコーポレーテッド | Apparatus and method for delivering fluid infusion boluses to patients and handling harmful fluids |
US20100145306A1 (en) * | 2008-07-24 | 2010-06-10 | Boston Scientific Scimed, Inc. | Various Catheter Devices for Myocardial Injections or Other Uses |
EP2361646B1 (en) | 2008-09-12 | 2013-03-20 | Roche Diagnostics GmbH | Dosing unit and ambulatory infusion device comprising dosing unit |
US7825392B2 (en) | 2008-10-08 | 2010-11-02 | Rodney Wayne Prosser | Cleaning process for radiopharmaceutical reusable pigs |
IT1395063B1 (en) | 2008-10-10 | 2012-09-05 | Tema Sinergie Srl | DEVICE AND APPARATUS FOR RAPIDING FRACTION AND THE INFUSION OF RADIOPHARMACEUTICALS. |
US9149605B2 (en) | 2009-07-28 | 2015-10-06 | Clement Kleinstreuer | Methods and devices for targeted injection of microspheres |
US8983574B2 (en) * | 2009-11-17 | 2015-03-17 | The Brigham And Women's Hospital | Catheter device with local magnetic resonance imaging coil and methods for use thereof |
US8696698B2 (en) | 2009-12-02 | 2014-04-15 | Surefire Medical, Inc. | Microvalve protection device and method of use for protection against embolization agent reflux |
US8500775B2 (en) * | 2009-12-02 | 2013-08-06 | Surefire Medical, Inc. | Protection device and method against embolization agent reflux |
US20110144576A1 (en) * | 2009-12-14 | 2011-06-16 | Voyage Medical, Inc. | Catheter orientation control system mechanisms |
WO2012006555A1 (en) * | 2010-07-09 | 2012-01-12 | Preventiv, Inc. | Two chamber syringe with locking mechanism |
EP2595682A4 (en) * | 2010-07-23 | 2014-01-01 | Safeshot Technologies Llc | Retractable safety syringe with non-loaded seal |
CN103282074B (en) * | 2010-11-03 | 2016-08-10 | 比尔卡地亚股份有限公司 | Endoluminal and method can be handled |
US9662458B2 (en) * | 2010-12-23 | 2017-05-30 | Richard A. Schatz | Injection needle insertion barrier |
FR2971425B1 (en) | 2011-02-10 | 2014-05-02 | Lemer Prot Anti X Par Abreviation Soc Lemer Pax | RADIOPROTECTION DEVICE FOR SYRINGE |
WO2012118687A1 (en) | 2011-02-28 | 2012-09-07 | Merck Sharp & Dohme Corp. | Manually operated injector with restricted injection sequence |
CN103702708B (en) * | 2011-05-23 | 2016-03-23 | 奈缇路有限公司 | For the development mechanism of vascular insertion apparatus in body |
EP2714138B1 (en) | 2011-05-25 | 2018-03-14 | Sanofi-Aventis Deutschland GmbH | Cartridge holder, medical device comprising such a cartridge holder and method for inserting a medicament reservoir |
GB201113606D0 (en) | 2011-08-05 | 2011-09-21 | Norbrook Lab Ltd | Dual chamber syringe |
JP6361027B2 (en) | 2012-01-23 | 2018-07-25 | ビー サイト リミテッド | Automatic cleaning syringe method and apparatus |
WO2013153722A1 (en) | 2012-04-13 | 2013-10-17 | テルモ株式会社 | Tube connection structure |
US9393441B2 (en) | 2012-06-07 | 2016-07-19 | Bayer Healthcare Llc | Radiopharmaceutical delivery and tube management system |
WO2014040143A1 (en) | 2012-09-17 | 2014-03-20 | Gray Bruce N | Method of treating cancer |
US9174003B2 (en) * | 2012-09-28 | 2015-11-03 | Bayer Medical Care Inc. | Quick release plunger |
US8671817B1 (en) * | 2012-11-28 | 2014-03-18 | Hansen Medical, Inc. | Braiding device for catheter having acuately varying pullwires |
US9486643B2 (en) | 2012-12-07 | 2016-11-08 | Emory University | Methods, systems and computer readable storage media storing instructions for image-guided treatment planning and assessment |
US9408981B2 (en) * | 2013-03-10 | 2016-08-09 | Bayer Healthcare Llc | Adjustable volume syringe |
US10071222B2 (en) * | 2013-03-16 | 2018-09-11 | Clph, Llc | Electrode catheters and methods for making them |
JP2014200361A (en) | 2013-04-02 | 2014-10-27 | テルモ株式会社 | Medical catheter and method for using the same |
US20160331853A1 (en) | 2014-01-21 | 2016-11-17 | The Trustees Of Columbia University In The City Of New York | Compositions for radiotherapy and uses thereof |
JP2017519725A (en) | 2014-05-08 | 2017-07-20 | サーテックス・メディカル・リミテッド | How to treat renal cell carcinoma |
WO2016049685A1 (en) | 2014-09-30 | 2016-04-07 | Sirtex Medical Limited | An administering device for administering a therapeutic substance |
AU2015327748B2 (en) | 2014-09-30 | 2021-04-08 | Sirtex Medical Limited | A transferring device for transferring a toxic substance |
CR20170245A (en) * | 2014-12-05 | 2017-09-14 | Edwards Lifesciences Corp | DIRIGIBLE CATETER WITH TRACTION CABLE |
US10765811B2 (en) | 2014-12-08 | 2020-09-08 | Genentech, Inc. | Versatile syringe platform |
BR112017014786B1 (en) * | 2015-01-09 | 2022-07-26 | Accurate Medical Therapeutics Ltd. | EMBOLIZATION MICROCATHETER |
WO2016161346A1 (en) | 2015-04-01 | 2016-10-06 | Osprey Medical, Inc. | Syringe volume monitoring systems with hall sensor |
CN106232173B (en) | 2015-04-02 | 2019-08-30 | 光阳产业股份有限公司 | Medical connection structure |
US20170065731A1 (en) | 2015-09-06 | 2017-03-09 | Medical Theranostics Inc. | Method, Apparatus, and System for Radiation Therapy |
WO2017053398A1 (en) | 2015-09-21 | 2017-03-30 | Board Of Regents, The University Of Texas System | Single catheter device for transvascular delivery of particulate and non particulate agents |
US20170106170A1 (en) * | 2015-10-19 | 2017-04-20 | Biocardia, Inc. | Multi-Directional Steerable Catheter |
CN108135591B (en) | 2016-02-24 | 2021-05-28 | 禾木(中国)生物工程有限公司 | Neurovascular catheter with enhanced flexibility |
WO2017157974A1 (en) | 2016-03-16 | 2017-09-21 | Koninklijke Philips N.V. | System for assisting in performing an interventional procedure |
CN107376093A (en) * | 2016-11-18 | 2017-11-24 | 苏州恒瑞迪生医疗科技有限公司 | Seal wire turns round control device |
US20170189569A1 (en) | 2017-03-16 | 2017-07-06 | Omid Souresrafil | Biodegradable microspheres incorporating radionuclides technical field |
EP3645058A4 (en) | 2017-06-28 | 2021-05-12 | The Regents of The University of California | Composite embolization beads |
MX2020012333A (en) | 2018-05-18 | 2021-01-29 | Bard Peripheral Vascular Inc | Radioembolization delivery device. |
EP3793620B1 (en) | 2018-05-18 | 2023-07-12 | Bard Peripheral Vascular, Inc. | Microspheres containing radioactive isotopes and other markers, and associated methods |
EP3793681B1 (en) | 2018-05-18 | 2023-10-18 | Bard Peripheral Vascular, Inc. | Microsphere containment systems and methods |
-
2019
- 2019-05-17 EP EP19728826.9A patent/EP3794608A1/en active Pending
- 2019-05-17 EP EP19733220.8A patent/EP3793659A1/en active Pending
- 2019-05-17 AU AU2019269701A patent/AU2019269701A1/en active Pending
- 2019-05-17 JP JP2020564539A patent/JP7361724B2/en active Active
- 2019-05-17 US US17/056,034 patent/US12011552B2/en active Active
- 2019-05-17 JP JP2020564538A patent/JP7482789B2/en active Active
- 2019-05-17 US US17/055,721 patent/US20210205584A1/en active Pending
- 2019-05-17 AU AU2019269705A patent/AU2019269705A1/en active Pending
- 2019-05-17 WO PCT/US2019/032965 patent/WO2019222687A1/en active Application Filing
- 2019-05-17 CN CN201980046620.XA patent/CN112384988A/en active Pending
- 2019-05-17 IL IL278811A patent/IL278811B2/en unknown
- 2019-05-17 CN CN201980046622.9A patent/CN112423822B/en active Active
-
2020
- 2020-11-18 IL IL278804A patent/IL278804A/en unknown
-
2023
- 2023-06-14 JP JP2023097742A patent/JP2023113944A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6669671B1 (en) * | 1998-12-22 | 2003-12-30 | Owais Mohammad | Retractable needle with dual locking mechanisms |
US6093170A (en) * | 1999-01-28 | 2000-07-25 | Hsu; Kuo-Chi | Structure safety syringe |
US20050267411A1 (en) * | 2004-05-28 | 2005-12-01 | Huang-Chuan Chen | Breakable syringe with a safety sleeve |
US20060258977A1 (en) * | 2005-05-02 | 2006-11-16 | Lee Martin N | Autoflush syringe |
US20100100033A1 (en) * | 2006-10-24 | 2010-04-22 | Control Medical Technology, Llc | Double barrel syringe and handles for use with double barrel syringes |
US20140276039A1 (en) * | 2013-03-13 | 2014-09-18 | Medrad, Inc. | Multiple compartment syringe |
US20200129695A1 (en) * | 2017-06-26 | 2020-04-30 | V.V.T. Med Ltd. | Actuator and device for synchronized injection and aspiration |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11179518B2 (en) * | 2020-02-27 | 2021-11-23 | Jubilant Draximage Inc. | Syringe shield assembly for housing and transporting a syringe containing radioactive drug |
US20220112951A1 (en) * | 2020-10-09 | 2022-04-14 | Enplas Corporation | Plunger, instrument, and mold |
US11933401B2 (en) * | 2020-10-09 | 2024-03-19 | Enplas Corporation | Plunger, instrument, and mold |
Also Published As
Publication number | Publication date |
---|---|
IL278804A (en) | 2021-01-31 |
CN112423822A (en) | 2021-02-26 |
JP2023113944A (en) | 2023-08-16 |
JP7361724B2 (en) | 2023-10-16 |
EP3794608A1 (en) | 2021-03-24 |
AU2019269701A1 (en) | 2021-01-14 |
IL278811B2 (en) | 2024-04-01 |
JP7482789B2 (en) | 2024-05-14 |
US20210205584A1 (en) | 2021-07-08 |
AU2019269705A1 (en) | 2021-01-07 |
JP2021524308A (en) | 2021-09-13 |
IL278811B1 (en) | 2023-12-01 |
EP3793659A1 (en) | 2021-03-24 |
CN112384988A (en) | 2021-02-19 |
CN112423822B (en) | 2023-04-14 |
IL278811A (en) | 2021-01-31 |
US12011552B2 (en) | 2024-06-18 |
WO2019222687A1 (en) | 2019-11-21 |
JP2021524307A (en) | 2021-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12011552B2 (en) | Dual-stage syringes for independent delivery of two or more fluids | |
US11839738B2 (en) | Medication infusion device | |
JP7345895B2 (en) | Systems and methods for safety syringes | |
AU668099B2 (en) | Medicament injector and method | |
US5704921A (en) | Prefilled hypodermic syringe system | |
JP6069481B2 (en) | Rotating needle magazine | |
US6666852B2 (en) | Axially activated vial access adapter | |
FI109661B (en) | Medical valve | |
CN112512631B (en) | Radioactive embolism delivery device | |
JP2005508656A (en) | Prefilled safe vial injector | |
JPH10295814A (en) | Cannula tight sealing shield assembly | |
EP1563863A1 (en) | Method of producing syringe, cap, and prefilled syringe | |
MXPA03008268A (en) | Pre-filled safety diluent injector. | |
US6277102B1 (en) | Hypodermic syringe system and method of manufacture | |
CN106714765B (en) | Device for connecting puncture bottles, corresponding method, hose or cartridge set and treatment unit | |
US3977402A (en) | Injection apparatus and method with automatic aspiration feature | |
KR20180050288A (en) | Drug packaging | |
JP5416529B2 (en) | Drug administration device and drug administration device with drug container installed | |
WO2019222699A1 (en) | Dual-stage syringes for independent delivery of two or more fluids | |
US20230270946A1 (en) | Vial geometries for optimal mixing | |
US20240164987A1 (en) | Injectable materials delivery devices, systems, and methods | |
US20230026471A1 (en) | Injectable materials delivery devices, systems, and methods | |
JP2020500622A (en) | Method and apparatus for filling a syringe with a retractable needle | |
JP2014131763A (en) | Medical device connector and medicament administration device | |
JP2003528699A (en) | Needleless syringe with prefilled cartridge |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: C.R. BARD, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AKERELE-ALE, OLADIPO PETER;HEBERT, CASEY TYLER;KINGMAN, AMANDA;AND OTHERS;SIGNING DATES FROM 20190517 TO 20190520;REEL/FRAME:055224/0493 Owner name: BARD PERIPHERAL VASCULAR, INC., ARIZONA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:C.R. BARD, INC.;REEL/FRAME:055224/0531 Effective date: 20190829 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
ZAAB | Notice of allowance mailed |
Free format text: ORIGINAL CODE: MN/=. |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |